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ABSTRACT

Traditionally, metastatic colorectal cancer has been treated using cytotoxic chemotherapy
but the development of immunotherapeutic agents has afforded higher durable remission
rates and more tolerable side effect profiles in a small subset of patients. Immunotherapy
treatments are currently approved for the treatment of microsatellite instability high
subgroup that comprises four percent of metastatic colorectal cancer. However,
immunotherapy treatments have little clinical activity in the microsatellite stable
subgroup, which encompasses the majority of colorectal cancers. In this phase II trial,
we propose to study the efficacy and safety of a three-drug regimen comprised of two
immunotherapy treatments, programmed death 1 and cytotoxic T-lymphocyte associated
protein 4 blockade, and a cyclooxygenase inhibitor in the microsatellite stable subgroup.
This combination aims to increase the treatment eligible proportion of colorectal cancers
by establishing a viable immunotherapy option for the microsatellite stable subgroup.

v

CHAPTER 1: INTRODUCTION
1.1 BACKGROUND
Immuno-oncology is a new paradigm in cancer treatment that has the potential to
provide unprecedented and robust tumor regression as well as increased survival
compared to traditional chemotherapeutic agents in several cancers even at an advanced
stage. The first immune checkpoint inhibitor (ICI), a human cytotoxic T-lymphocyte
antigen 4 (CTLA-4)-blocking antibody named ipilimumab (Yervoy; Bristol Myers
Squibb) was approved in 2011 and many others began development based on its
unmatched success.1 ICIs are now a standard of care for various cancer types such as
metastatic melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma.2
In colorectal cancer (CRC), immunotherapies have achieved remarkable efficacy
shown by significantly prolonged progression free survival (PFS) and safety profiles that
are favorable compared to traditional chemotherapy, but only in a small subset. Three ICI
therapies were approved recently for a small subset of metastatic colorectal cancers
(mCRC): pembrolizumab (Keytruda), nivolumab (Opdivo) and the combination
treatment nivolumab and ipilimumab (Yervoy).3-5 This subset is comprised of patients
with the biomarker called microsatellite instability high (MSI-H) or deficient mismatch
repair (dMMR) that makes up 15-20% of the CRC and about 4% of the mCRC
population.6
1.2 STATEMENT OF THE PROBLEM
While immune checkpoint inhibitors are capable of causing tumor regression and
improved overall survival with fewer side effects compared to traditional chemotherapy,
only a minority of the CRC patients responds to treatment. The importance of increasing
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the response rate of ICIs in CRC and specifically in microsatellite stable/proficient
mismatch repair (MSS/pMMR) colorectal cancer is paramount.
1.3 GOALS AND OBJECTIVES
Prior preclinical data suggest that the combination of checkpoint inhibition and COX
inhibition might achieve a higher response rate in a subset of MSS CRC patients.
The aim of this study is to find whether the combination treatment of anti-PD-1/antiCTLA4 and anti-COX treatment will enhance the response rate in MSS mCRC, while
maintaining an adequate safety profile. We will also evaluate the efficacy measures of
PFS and OS, toxicity profiles and associations with known biomarkers.
1.4 HYPOTHESIS
This parallel assignment, randomized allocation phase II trial is designed to study the
hypothesis that the combination of PD-1 and CTL4 blockade and COX-2 inhibition or
COX-1 and 2 inhibition significantly increases the objective response rates (ORR)
(23.7%) compared to the historical response rate of 8.7% with PD-1/CTL4 blockade
alone in MSS/pMMR mCRC that has progressed on previous treatment with cytotoxic
chemotherapy with irinotecan, fluorouracil and oxaliplatin. The expected effect size of
15% will be tested for statistical significance.
1.5 DEFINITIONS
PD-1: Programmed death 1 receptor, co-inhibitory receptor found on effector T cells
PD-L1: Programmed death ligand 1 found on tumor cells
CTLA-4: Cytotoxic T-lymphocyte associated protein 4, co-inhibitory receptor found
on recently activated T cells
CD80/CD86: Ligand for CTLA-4, found on tumor-associated antigen presenting cells
(APCs)
Pembrolizumab (Keytruda): Humanized anti-PD-1 antibody (Merck & Co.)
Nivolumab (Opdivo): Fully human anti-PD-1 antibody (Bristol-Myers Squibb)
Ipilimumab (Yervoy): Fully human anti-CTLA-4 monoclonal antibody (BristolMyers Squibb)
Celecoxib (Celebrex): A selective COX-2 inhibitor (Pfizer)
ASA: Aspirin, a dual COX-1 and COX-2 inhibitor
2

FOLFOX: Combination chemotherapy containing oxaliplatin with fluorouracil (5FU)
and folinic acid
FOLFIRI: Combination chemotherapy containing fluorouracil (5FU), folinic acid and
irinotecan
FOLFOXIRI: Combination chemotherapy containing oxaliplatin with fluorouracil
(5FU), folinic acid and irinotecan
Capecitabine (Xeloda): Antimetabolite chemotherapy agent (generic)
5FU(Adrucil): fluorouracil, an antimetabolite chemotherapy agent (generic)
Irinotecan (Campostar): Topoisomerase inhibitor chemotherapy agent
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CHAPTER 2: REVIEW OF THE LITERATURE
2.1 INTRODUCTION
We searched relevant clinical trials; articles and conference abstracts published in the
English language in PubMed and Ovid MEDLINE, Cochran Review and
ClinicalTrials.gov between the years 1980 and 2018. The searches were conducted with
the MeSH subject headings of “immunotherapy”, “colorectal cancer”, “metastatic”,
COX-2 inhibitors” and “microsatellite stable”. Other non-MeSH terms we searched were
“deficient mismatch repair”, “proficient mismatch repair”, “checkpoint inhibitor”, COX
inhibition” and “combination therapies”.
2.1a Incidence of Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer as well as third leading
cause of cancer mortality in the US7 and the second leading cause of cancer mortality
worldwide.8 Although the recent advances in screening improved both incidence and
mortality rates, The National Cancer Institute estimates that there will be 140,250 new
cases and 50,630 deaths associated with CRC in the United States in 2018. CRC
comprises 8.1% of new cancer diagnoses and the median age at diagnosis is 67. mCRC or
Stage IV CRC that is defined by spread of the disease to distant sites in the body,
comprises 21% of the CRC population. The incidence is slightly higher in men than
women, and in African Americans, compared to other races.9
2.1b Prognosis
Based on data from Surveillance, Epidemiology and End Results (SEER) from 2008
to 2014, the overall 5-year survival rate for CRC is 64.5% in the US. The 5-year survival
rate for localized CRC is 89.8%, for regional is 71.1%, and for distant metastases is
13.8%.9 Prognostic biomarkers are lymph node involvement, presence of metastases,
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right- vs. left-sided tumor, microsatellite instability (MSI-H)/deficient mismatch repair
(dMMR) vs. microsatellite stable (MSS)/proficient mismatch repair (pMMR), KRAS,
BRAF and NRAF mutation status.10
2.1c Current Treatment Guidelines
As metastatic tumors are rarely resectable or treatable solely by radiation and
generally require systemic treatment. The main systemic treatment options for mCRC are
traditional cytotoxic chemotherapy, anti-VEGF or EGFR therapy. 10
First line chemotherapeutic agents such as FOLFOX, FOLFIRI, Capecitabine and
5FU/leucovorin have been used with or without the anti-angiogenic agent bevacizumab.
For high tumor burden or rapidly progressing disease the quadruple chemotherapy
FOLFOXIRI can be considered. These agents can be used as neo-adjuvant therapy or
post-resection and are generally administered every 2-3 weeks for several cycles. The
efficacy and response rate of chemotherapy varies based on the regimen. In a
representative study looking at chemotherapy versus chemotherapy with an antiangiogenic agent, overall survival (OS) in mCRC was 15.6 months with IFL (irinotecan,
5FU and leucovorin) and 20.3 months with IFL plus bevacizumab, corresponding to a
hazard ratio of 0.66 for death (p<0.001). The response rates were 44.8% and 34.8%
respectively.11
For refractory mCRC the drugs regorafenib or trifluridine/tipiracil are recommended
and offer a modest survival benefit.10 A meta-analysis evaluating data for 702 patients in
12 studies, assessing the efficacy of regorafenib found summary progression free survival
rates of 3.34 months and overall survival rates of 7.27 months but the response rate was a
modest 2%.12 The side effects of chemotherapy vary based on the combination but the
most commonly reported are diarrhea, fatigue, myelosuppression, neuropathy, hair loss
6

and cold sensitivity. Some side effects, such as neuropathy can be treatment limiting and
irreversible.10
Recent advances in immunotherapy afforded new checkpoint blockade options for a
small subset of mCRC patients, discussed in Section 2.2.
2.2 REVIEW OF EMPIRIC STUDIES
2.2a Immune Checkpoint Inhibitors in the Treatment of Colorectal Cancer
The immune system recognizes foreign invaders such as bacteria and viruses but it
can also mount an attack against our own deviant cells, such as cancer cells. Attributed to
the number of mutations they accumulate, cancer cells can display abnormal epitopes
called neo-antigens on their surface. Neo-antigens recognized by the immune system can
trigger an immune attack leading to the destruction of the cancer cells. Checkpoints built
into the system to help curb aberrant autoimmune reactions toward healthy cells. The coreceptor portion of his double system, consisting of the antigen presented by an antigen
presenting cell (APC) and a co-receptor whose activation can prevent immune system
activation is a frequent target of cancer immune evasion. Some neoplasms acquire
mechanisms to evade destruction by T-cells by hijacking these checkpoints leading to the
dampening or curbing of the immune attack despite neo-antigen recognition. This
immune evasion generally takes place by negative regulation of T-cell activation either
during primary activation or during the memory forming immune response phase.1
The two most well studied of these checkpoints are cytotoxic T-lymphocyteassociated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) and its ligand
programmed death-ligand 1(PD-L1). CTLA-4 is a co-inhibitory receptor found on
recently activated T cells whose ligand is found on tumor associated APCs. PD-1
receptors work as co-inhibitory receptors on effector T cells. Their ligand, PD-L1,
7

programmed death ligand 1 is found on tumor cells. Many other newly discovered
checkpoints are now being investigated as future therapeutic targets.
Immune checkpoint inhibition (ICI) is a strategy that aims to stimulate immune cells,
mainly T cells. Several ICI agents have emerged, commonly targeted pathways being
PD-1 using the humanized antibody pembrolizumab, or the fully human antibody
nivolumab. Anti-CTLA-4 antibodies such as the fully human antibody ipilimumab are
also available.
Releasing these breaks to aid tumor destruction via checkpoint inhibition has
achieved unprecedented success in treating certain tumor types. A meta-analysis of 13
studies with 3,513 immunotherapy treated small cell lung cancer patients and 3,072
chemotherapy/placebo treated patients found greatly improved progression free survival
(PFS)(odds ratio 1.81, [95% CI 1.36, 2.42; P<0.0001]) and overall survival (OS)
(P<0.0001).13
While ICIs can cause sustained responses in selected patients, based on cancer type
and specific host tumor markers, there are several obstacles to be overcome. One of the
most pressing concerns is the low response to immune checkpoint inhibitor monotherapies. The response rates have been inconsistent both amongst different types of
cancers, and histologically different cancers within a specific cancer type. The overall
response rate to immune checkpoint therapy ranges from 15% with ipilimumab14 to up to
40% with PD-1/PD-L1 blockade, including those patients whom only achieved a partial
response to treatment.15 The response rates can be as high as 61% in melanoma with PD1/CTLA-4 (nivolumab/ipilimumab) treatment16 however, melanoma has been showing
higher objective response rates compared to other types of cancer. Thus, with the
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exception of melanoma, ICI response rates are between one quarter to one half of
recipients.
It is vital to improve both the response rate to immune checkpoint inhibitor treatments
in mCRC as well as to increase the efficacy of the treatment signified by extended
progression free survival (PFS) and overall survival (OS). The discovery of biomarkers
that can identify patients who are likely to respond to checkpoint inhibitor treatment is
crucial to achieving this goal.
Mismatch repair (MMR) or microsatellite instability (MSI) are biomarkers that have a
large impact on ICI treatment response rates and prognosis. Mismatch repair is a
mechanism cells use to repair DNA damage during cellular replication. Mismatch repair
deficient (dMMR) or Microsatellite Instability High (MSI-H) is a small subset of CRC
that has a high mutation rate. A higher mutation burden translates into a larger number of
neo-antigens displayed in cancer cells’ MHC I molecules. Antigen presentation renders
these tumors easier to be recognized by the adaptive immune system, higher density of
TIL (tumor infiltrating lymphocytes) leading to a more efficient elimination by ICIs.17
This increased immunogenicity in MSI-H tumors is termed as being “hot”, versus MSS
tumors that are labeled “cold” tumors based on their diminished immunogenicity
attributed to the lack or paucity of TILs.18
Historically, the MSI-H/dMMR and MSS/pMMR subsets of CRC respond very
differently to single agent immunotherapy. While in MSI-H/dMMR CRC the objective
response rate was 40%, to the anti-PD-1 antibody pembrolizumab (Keytruda Merck &
Co.), there was no objective response for MSS/pMMR CRC.5
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Generally, the dMMR/MSI-H subset comprises only 15-20% of all colorectal cancers,
and as the stage of the disease increases, the portion of the dMMR/MSI-H CRC
decreases. Only 4% of Stage IV CRC is dMMR/MSI-H.6 Thus, only a very small portion
of mCRC lends itself to ICI treatment, with the majority of mCRC that is MSS/pMMR
failing to demonstrate meaningful clinical activity.
As the MSI-H/dMMR tumor biomarker is predictive of response to PD-1 checkpoint
inhibitor therapy6, guidelines published by the American Society of Clinical Pathology,
College of American Pathologists, Association of Molecular Pathology and the American
Society of Clinical Pathology recommends universal MSI and mismatch repair (MMR)
testing in all mCRC patients since 2017.19 See Appendix B for MMR testing and MSI
classification. As only 4% of the mCRC population possesses this biomarker, the
majority of mCRC patients are excluded from ICI treatment options. It is paramount to
further elucidate the differences, especially regarding molecular patterns, cytokine
expression and tumor infiltrating lymphocyte (TIL) content between MMS and MSI-H
tumors.17
Although mutation burden and in turn the number of neo-epitopes cancer cells display
in a specific tumor seem to be the most important factor in predicting response to ICIs, a
new paradigm in immune-oncology recognizes that other factors are at play, especially
given that the MSI-H/MSS classification does not always correlate with response to ICI
therapy. In fact, genomic profiling of tumors from over 6000 patients found that about
3% of MSS CRC have high mutation burden (HMB MSS).20 Of note, some MSS/pMMR
tumors have high T-helper cell infiltration, cytotoxic gene content, cytokine and
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chemokine expression similarly to their MSI-H/dMMR counterpart and importantly, have
similar prognosis.17
The best ICI response rates were seen in MSI-H/dMMR CRC, but even with the
combination of ipilimumab and nivolumab, only a little more than half of this population
responds. Although microsatellite instability is not a perfect marker for ICI response, it is
the strongest one we have. The challenge is to coax the MSS tumors to behave more like
their MSI-H counterparts.17 Current advances in using Immunoscore as a new biomarker
might yield a better indicator for checkpoint therapy success. If we accept Immunoscore
as a valid predictor of response rate, the challenge will become to increase a certain
tumor’s Immunoscore.
Immunoscore is a scoring system based on the density of CD3+ and CD8+ T-Cell
effectors within the tumor and its invasive margin.21 It was validated for Stage I-III CRC
by a large international consortium.21 Another study found that Immunoscore is also
predictive of DFS (disease free survival) and OS (overall survival) in mCRC.22 Refer to
Appendix C for the description of the Immunoscore scoring system.
The two ICI monotherapies approved for chemotherapy pre-treated MSI-H/dMMR
mCRC are pembrolizumab and nivolumab.3-5 The first agent to be approved was the antiPD-1 antibody pembrolizumab, based on studies conducted on eleven cancer types,
including CRC. In this study 52% of CRC patients responded to pembrolizumab and the
estimated 1-year PFS was 64%. As per protocol, the patients stopped therapy at 2 years
and none had recurrence at the median follow up of 8 months.5 The extended durable
response suggests conceivable curative potential that must be followed up for a longer
duration.

11

Nivolumab, another PD-1 blocker was approved for MSI-H/dMMR CRC patients
who progressed on traditional chemotherapy after the Nivolumab monotherapy arm of
the CheckMate 142 trial found a 31.1% response rate in MSI-H/dMMR CRC with a
corresponding 1-year survival of 50%.3
2.2b Clinical Efficacy of Ipilimumab and Nivolumab
The complexity and redundant nature of cellular signaling often favors combinatorial
treatments. Ongoing efforts aim to test combinations of ICI and radiation, targeted
therapy, chemotherapy and anti-angiogenic agents.2 These combinations can either block
a single checkpoint pathway more effectively such as concurrent PD-1/PD-L1 blockade
or simultaneously target distinct pathways. Attempts to combine different ICIs such as
anti-CTLA-4 ipilimumab and the anti-PD-1 nivolumab (Opdivo; Bristol-Myers Squibb)
have been increasingly effective in several cancer types including colorectal cancer2.
Just recently, based on the results of the CheckMate 142 study, ICI therapy using the
anti-PD-1/anti-CTLA4 nivolumab and low dose ipilimumab was approved for MSIH/dMMR CRC that has progressed following treatment with a fluoropyrimidine,
oxaliplatin, and irinotecan.23 The response rate using this combination improved to 55%
over 31.1% with nivolumab only and the 1-year survival increased to 71% from 50%.
The price of higher response rate and efficacy was higher frequency of CTCAE Grade 3
and 4 adverse events that increased from 20% with nivolumab only, to 32% with the
combination. These adverse events, however, were overall manageable.4
While the Phase II study CheckMate 142 focused on the combination of CTLA-4
blockade and PD-1 blockade in the MSI-H mCRC patient population, responses were
also seen amongst the much smaller arm consisting of MSS patients. 23 MSS patients
were enrolled of which two patients responded with a median PFS of 1.4 months (1.2 and
12

1.9 months). The median PFS was minimal compared to the MSI-H/dMMR cohort’s that
was not reached after 33 PFS events. It is notable that the responses were not associated
with tumor PD-L1 expression levels in either cohort. Furthermore, responses were not
associated with BRAF/KRAS mutation or history of Lynch syndrome in the MSIH/dMMR cohort.4
While these results are promising, addition of an immunomodulating drug could
increase ORR and improve survival in both subgroups.
2.2c Immune Mediated Adverse Events using Nivolumab and low-dose Ipilimumab
Treatment related adverse events (TRAEs) associated with nivolumab and low dose
ipilimumab treatment, are mainly immune mediated adverse events (IMAE). IMAEs can
affect any of the main organ systems and have a diverse range of manifestation. During
the CheckMate 142 trial the most common TRAEs found were diarrhea (22%), fatigue
(18%) and pruritus (17%) followed by pyrexia and elevated AST (15%).4 The in depth
safety analysis was published separately.24 TRAEs resolved in the majority of the patients
(71-96%), except for endocrine adverse events which only resolved in 40% of patients.
The discontinuation rate due to an adverse event (AE) remained low at 13% and there
were no treatment related deaths reported.
The addition of COX-inhibitors in the current study might modulate these adverse
events, which will be closely monitored and recorded throughout the study with the goal
of early recognition, as early recognition and treatment of IMAEs with or without the
need for steroids, could improve outcomes in ICI treatment.25 See Appendix D for
Common Terminology Criteria for Adverse Events (CTCAE) grades.
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2.2d Management of Immune-related Adverse Events
Immune related adverse events (irAE) will be managed by the recommendations set
forward by the American Society of Clinical Oncology (ASCO) Clinical Practice
Guideline, briefly outlined in Appendix R. For further information and organ specific
management, refer to the published guidelines.25
2.2e The Role of the COX Pathway in Colorectal Cancer
In this section we will discuss the role of COX pathway in colorectal cancer and
specifically in MSS CRC and few of the mechanisms that are thought to be at play.
COX-2 is overexpressed in many human cancers such as colorectal, pancreatic, lung,
breast and stomach cancers.27 Additionally, research in different cancer types show that
microsatellite instability has an inverse relationship with COX-2 expression levels. In
gastric cancer, microsatellite instability is inversely proportional to COX-2 expression. 28
Karnes et al. found that a subset of colorectal carcinomas with microsatellite stable
phenotype (MSS) shows increased expression of COX-2 compared to colon cancer with
the MSI-H phenotype.29 Furthermore, response to COX-2 inhibitors is reduced in cell
lines with reduced COX-2 expression in in vitro experiments.30 The COX-2
overexpression in MSS CRC therefore could be predictive of COX-2 inhibitor treatment
success.
The COX-2 enzyme can be inhibited both by steroids (by inhibiting the release of the
COX substrate arachidonic acid) and non-steroidal anti-inflammatory drugs (NSAIDs)
that either inhibit COX-1 and COX-2 enzymes or selectively inhibit COX-2.31 COX-1/2
(Aspirin, Bayer) or selective COX-2 inhibitors such as celecoxib (Celebrex, Pfizer) are
readily available on the US market.
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The product of the COX-2 pathway is prostaglandin E2 (PGE2), a vital homeostatic
factor that has a wide range of functions in many body systems, including several roles in
modulating immune responses.31 The COX-2 pathway plays a dual role in cancer.
Paradoxically, while PGE2 is considered to be a mediator of inflammation via activation
of dendritic cells, it has also been shown to suppress innate and antigen-specific immune
responses by suppressing the dendritic cells’ ability to interact with naïve, effector and
memory T-cells, and suppressing other effector functions associated with cytotoxic Tcells (CTL) and natural killer cells (NK). Thus while PGE2 stimulates acute local
inflammation, it suppresses immune function by effector cells such as CTL, T-helper
1(Th1) and NK cells, especially in the later stages of inflammation.31 This is thought to
prevent the tissue-damaging actions of nonspecific inflammation during chronic
inflammatory conditions such as chronic infections or cancer.32.33 PGE2 is also implicated
in promoting angiogenesis.33 Together PGE2’s angiogenic effect, T-cell suppressive and
pro-inflammatory activities contribute to immune evasion and are advantageous for
tumor formation.31
Another proposed function that may contribute to the COX pathway’s T-cell
suppressive action is it’s direct involvement with checkpoint molecules such as PD-L1 an
important target of ICI therapy. Botti at. Al found that COX-2 expression positively
correlates with PD-L1 expression in both primary tumors and metastases in melanoma in
vitro.34 Furthermore, inhibition of COX-2 by celecoxib down-regulated the expression of
PD-L1 in two different human melanoma cell lines.34
Another proposed mechanism for the COX pathway’s involvement in immune
checkpoint blockade is the inhibition of the indoleamine 2,3-dioxygenase 1 (IDO1)
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pathway. IDO1 has an essential role in regulating tryptophan catabolism by degrading
tryptophan and therefore represses tryptophan-dependent T-cell populations,35 a
mechanism that is at least in part responsible for the tumor immune escape. Hennequart
and colleagues showed that COX-2 expression drives constitutive expression of IDO1
which in turn represses the T-cells in human tumor cells in seven human cell lines,
including colorectal cancer. COX-2 inhibition by celecoxib treatment promoted rejection
of IDO1 expressing human tumor xenografts. Of note, the reduction of IDO1 was
associated with infiltration by CD3+ and CD8+ T cells.35
The most compelling argument for using anti-inflammatory drugs such as COX
inhibitors (alone or in combination with ICIs) is the elimination of chronic inflammation
that leads to immunosuppression, by inhibiting myeloid-derived suppressor cells
(MDSCs). MDSCs are myeloid precursors that are unique to cancer, and less frequently
to autoimmune diseases,38 thus they are an excellent target for anti-cancer drug
development. Their exclusive role is to provide a protective environment to cancer cells
and they were found to be the most important mediator of chronic inflammation, which in
turn, leads to immunosuppression.39
The tumor microenvironment (TME) that includes the stroma and infiltrating cells is
gaining attention as an important site of immune modulation. The TME has several cell
types that help protect cancer cells by secreting cytokines and chemokines thereby
altering myelopoiesis. Out of these tumor harboring cell types MDSCs seems be the most
crucial, by promoting the formation of Tregs and other cell types that help protect cancer
cells and are instrumental in promoting immune tolerance.40
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Targeting MDSCs, is a complex problem. The candidate drug needs to be an antiinflammatory drug without the immune-suppressive effects.41 COX inhibitors, such as
celecoxib or aspirin fit this description in that they decrease inflammation and are not
immunosuppressive but do not target cytokines of chronic inflammation as a
monotherapy.42 However in combination with ICI they were shown to decrease both
MDSCs, Tregs and immunosuppressive cytokines. The preclinical murine study that
explored the effect of celecoxib plus PD-1 blockade in melanoma and breast cancer cells
found reduced MDSC and Treg population in the TME, as well as reduced cytokines IL1β and IL-6. The other preclinical murine study also reported reduced cancer promoting
growth actors and chemokines, including IL-1, IL-6 and IL-8.43 Importantly, MDSCs, the
chronic inflammation marker C-reactive protein and the immune suppressive cytokines
can be measured.38
In summary, COX inhibitors decrease inflammation and are not immunosuppressive
but do not target the cytokines of chronic inflammation as a monotherapy,42 thus are not
thought to be effective in preventing tumor progression. In the murine study conducted
by Zelenay et. al. COX inhibition had no effect on the progression of implanted COXcompetent melanoma cells.27 COX inhibitors have been used as primary or secondary
prophylaxis or as an adjunct to other modalities in colorectal adenomas with moderate
efficacy, discussed in the next section.
2.2f Clinical Efficacy of COX Inhibition
Celecoxib and aspirin have both been used in colon adenocarcinomas as chemopreventive agents. A large study that followed up four randomized trials and pooled
individual patient data of over 14,000 patients showed that the long-term use (mean
duration of 6 years) of an at least 75mg daily dose of aspirin reduced the long-term
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incidence and mortality due to CRC. The 20-year risk of colon cancer was reduced in the
cohort taking aspirin (incidence hazard ratio [HR] 0.76, 0.60-0.96, p=0.02), and also
reduced mortality (HR 0.65, [95% CI, 0.48-0.88, p=0.005]).44 Although the studies being
analyzed differed in many characteristics including median duration of treatment,
methods of post trial follow up or proportion of current smokers, they were all double
blinded placebo controlled trials. This analysis demonstrates the degree to which aspirin
monotherapy was able to affect patients even after years of treatment.
A much larger meta-analysis of 281,063 CRC patients in 37 RCTs found that aspirin
reduced CRC incidence and mortality in a dose dependent manner (risk ratio [RR], 0.74
[95% CI, 0.57-0.97]) for high-dose (≥325 mg daily dose) and (RR, 0.81 [95% CI, 0.670.98]) for very-low-dose (≤100 daily dose)).45 Although the previous two meta-analyses
used different statistical methods, they both showed association of chemopreventive
aspirin use and reduced mortality and the second meta-analysis showed a dose dependent
relationship.
Similarly, celecoxib monotherapy was shown to be efficacious in secondary
prevention. A systematic review that examined three RCTs and three post-trial studies of
6,559 patients found that celecoxib doses between 400-800mg/day, when used for the
duration of 1-3 years showed statistically significant reduction of the recurrence of
advanced colorectal adenomas (RR 0.42 [95% CI, 0.34-0.53]) compared to placebo.
Subgroup analysis using 400mg/day celecoxib demonstrated very similar effects on
advanced adenomas (RR 0.45, [95% CI, 0.35-0.58]) compared to placebo, regardless of
the dosing regimen of 200mg twice or 400mg once daily.46
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Celecoxib is also used as an adjunct in addition to anticancer agents in the treatment
of several cancer types. A large meta-analysis that analyzed data from 11 trials found that
when used in combination with cytotoxic chemotherapeutic agents in advanced
colorectal, non-small cell lung cancer (NSCLC), prostate, breast and ovarian cancer,
celecoxib significantly increased the objective response rate (ORR) (RR 1.20, [95% CI,
1.06-1.36, P=0.005]) but had no effect on 1-year mortality (RR 1.02; [95% CI, 0.92-1.13;
P = 0.68]).47
These studies provide evidence for aspirin or celecoxib use for primary and secondary
prevention or as an adjunct in CRC. The new 2016 USPSTF guideline now suggests the
use of <100mg daily dose of aspirin for primary CRC prevention for patients without
bleeding risk.48 In summary, COX inhibition offers some protection against colorectal
cancer but is not intended as a monotherapy for treatment.
2.2g Drug-Related Adverse Events Associated with COX Inhibitors
The most common side effects of aspirin are GI disorders such as heartburn, nausea,
vomiting and abdominal pain. Elevated liver enzymes were also reported as well as very
rare cases of renal impairment and acute renal failure. Bleeding time is also prolonged,
leading to increased risk of bleeding.78
The most serious adverse events associated with the use of aspirin are gastrointestinal
bleeding, hemorrhagic stroke53 and less frequently aspirin-exacerbated respiratory
disease. A meta-analysis found the incidence of GI bleeds in 65,987 patients taking 501500 mg daily dose of aspirin for the mean duration of 28 months to be 2.47% compared
to 1.42% in patients taking placebo.49 Thus, the incidence of GI bleed associated with
aspirin use remains low. Furthermore, bleeding risk with low to high doses of aspirin
currently approved was found to minimal and the regimen was deemed safe for
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chemoprevention in CRC. A large systematic review and meta-analysis examining
281,063 patients in 37 RCTs taking aspirin for chemoprevention found the dose range of
75-325 mg/day safe regarding cardiovascular mortality and major GI bleeding among
patients of average risk.45
The most common side effects of celecoxib are also GI symptoms, such as dyspepsia,
abdominal pain, nausea and diarrhea.79 Celecoxib has a more favorable safety profile
compared to other non-selective NSAIDs regarding the risk of gastrointestinal injury.
Celecoxib was found to have significantly lower incidence of endoscopically observed
duodenal ulcers compared to 500mg twice-daily Naproxen. Doses from 50mg up to
400mg twice daily were studied and scientists found no correlation between celecoxib
dose and the incidence of duodenal ulcers.50 Concerns remain regarding the increased
cardiovascular risk of thromboembolism associated with selective COX-2 inhibitors. A
large randomized controlled trial (PRECISION) that recruited 24,081 arthritis patients
found that 100mg twice daily celecoxib was non-inferior to other NSAIDs such as
ibuprofen or naproxen regarding cardiovascular risk.51 The cardiovascular risks were
found to be similarly low in the CRC population. A meta-analysis that included
randomized controlled trials and post-trial studies of 6579 CRC patients investigated the
efficacy and safety of various celecoxib doses (200mg twice daily, 400mg daily or
400mg twice daily) versus placebo for secondary chemoprevention in CRC found the
400mg once daily dosing to be optimal without increasing cardiovascular risks.
Cardiovascular risk compared to placebo with the 400mg once daily dose was 1.01 [95%
CI, 0.70-1.46]. The 400mg twice-daily doses lead to as significant increase of serious
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cardiac events (3.42 [95% CI, 1.56-7.46]).46 Of note, the currently approved doses of
celecoxib are 200-400mg daily for osteoarthritis and rheumatoid arthritis.52
2.2h Management of Drug-Related Adverse Events associated with COX Inhibitors
Patients who are considered high risk for aspirin associated GI bleed, such as patients
with previous GI bleed or ulcer or concomitant use of clopidogrel will be excluded from
the study. Patients enrolled in the study will be closely monitored for signs and symptoms
of GI bleed.
The most effective strategies for reducing the risk of aspirin related upper GI bleed is
switching to an alternative antiplatelet therapy or concomitant use of proton pump
inhibitor.54 Proton pump inhibitors will be offered to patients as a prophylactic measure.
As switching to an alternative therapy is not an option in this case, aspirin use might have
to be discontinued in cases of serious GI bleeding.
A possible adverse effect associated with both aspirin and selective COX-2 inhibitors
is aspirin-exacerbated respiratory disease (AERD) that presents with moderate to severe
asthma symptoms and rhinosinusitis. Patients with asthma or asthma known to be
exacerbated by aspirin use are excluded from the study. Management of AERD includes
discontinuing aspirin or COX-2 inhibitor use and pharmacological management of
asthma symptoms and chronic rhinosinusitis.55
Interruption of treatment with aspirin or celecoxib will be permitted in case of the
need for elective surgery or biopsy. Aspirin and celecoxib will be discontinued 7 days
prior to the date of surgery and will be resumed at the surgeon’s discretion.
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2.2i Preclinical and Clinical Data Regarding Combination Checkpoint Inhibition
and COX Inhibition
Several pre-clinical works using in vivo animal models and in vitro human cell
cultures and some clinical data of ad hoc data or tissue marker analysis of large
prospective cohort studies shows promise for the combination of PD-1 blockade and
COX-2 inhibition in CRC and multiple other cancer cell lines.27,43,56 Accumulating
evidence indicates that the combination of checkpoint inhibition and COX-2 inhibition
could be a viable treatment option for several cancer types as an adjunct to ICI. The
combination of COX inhibitors and PD-1 blockers resulted in decreased tumor growth
compared to PD-1 monotherapy alone in murine melanoma models.27 The inhibition of
the COX-2 pathway combined with anti-PD-1 therapy improved the eradication of
tumors and increased the number of tumor-specific cytotoxic T lymphocytes (CTLs) in
human cell cultures from advanced ovarian cancer patients.56
The seminal work by Zelenay at. al. presented compelling pre-clinical evidence for
the use of COX inhibition as an adjunct to ICIs. His team found that COX inhibition
works synergistically with checkpoint inhibition via anti-PD-1 blockade inducing
eradication of tumors in in vivo experiments using the CT26 syngeneic murine colorectal
tumor model. Of note, the CT26 murine colorectal cells were found to share molecular
features with MSS colorectal tumors.57 In their immunomic, genomic and transcriptomic
characterization study, Castle and colleagues found that CT26 cells lack mutations in the
Mlh1 and Msh2 mismatch repair genes that are associated with microsatellite instability.
CT26 cells were also found to lack a Braf gene mutation that is also frequently associated
with the MSI-H phenotype. Overall CT26 cells were found to have a molecular makeup
that resembles aggressive, undifferentiated, refractory human colorectal cancer cells.57
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Zelenay and colleagues showed that COX induces PGE2 in tumors that disrupts
myeloid function and propose that PGE2 dependent suppression of myeloid cell
activation could be an additional mechanism of tumor immune escape in addition to the
immunoediting process whereby the immune system selects for less immunogenic tumor
cells. Furthermore, they showed that COX ablation in tumors re-establishes immune
control. A possible mechanism investigated by the researchers was the reduction of tumor
promoting factors such as Interleukin 6 (Il6) and Il1β expression by COX ablation
leading to increased levels of antitumor pathway mediators.
Importantly, similar effects were achieved by pharmacological reduction of PGE2
levels. They propose that COX inhibition synergizes with checkpoint blockade therapy
via anti-PD-1 blockade, and its efficacy is higher than either PD-1 blockade or COX
inhibition alone. This synergistic effect of COX inhibition and ICIs could revolutionize
ICI therapy in colorectal cancer. Since the COX inflammatory signature and signaling
pathway is conserved in humans27, and its inhibitors are readily available, it is a viable
target of investigation in clinical studies.
Another pre-clinical study explored the effect of local and systemic delivery of
celecoxib and PD-1 blockade on melanoma and breast cancer in tumor-bearing mice.
Researchers found that the treatment elicited potent and sustained antitumor effect by
enhancing T cell immunity, reduced immunosuppression and reducing inflammation and
tumorigenesis.43 The drug combination acted synergistically, to enhance the presence of
CD4+ interferon (IFN)ϒ+ and CD8+ IFNϒ+ T cells both within the tumor and in the
immune system. Importantly, the combination treatment reduced myeloid derived
suppressor cells (MDSC) and Tregs in the tumor environment. MDSC promote Tregs and
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is a marker for chronic inflammation. Once again, Il-6 and Il-1β were shown to be
suppressed, leading to diminished angiogenic and pro-inflammatory tumor
microenvironment. Thus, combination PD-1 blockade and COX-2 inhibition
simultaneously targeted both the immunosuppressive network and the chronic
inflammation in the tumor environment, both of which are thought to dampen ICI
therapeutic efficacy.39 Of note, PD-1 blockade caused an increase of PGE2, which was
subsequently completely abolished by celecoxib treatment.
Aspirin (a dual COX-1 and COX-2 inhibitor and antiplatelet agent) may be more
effective in synergizing with ICIs than selective COX-2 inhibition by celecoxib. Zelenay
and colleagues found that aspirin was more effective than celecoxib in tumor eradication
when combined with PD-1 inhibition in mouse experiments.27 The increased efficacy of
dual COX inhibition is thought to be due to the inhibition TGF-β (released by platelets)
associated with COX-1 inhibition and anti-platelet activity. TGF-β is thought to attenuate
tumor response to PD-L1 blockade by contributing to the exclusion of CD8+ T-cells.58
TGF-β is even thought to be one of the main drivers of immune evasion in colon cancer
metastasis.59 In mouse experiments, COX inhibition alone using aspirin had no effect on
the progression of implanted melanoma cells, compared to the effect with combination
with anti-PD-1 therapy where COX inhibition promoted a much more rapid tumor
regression than anti-PD-1 alone, and notably was more efficacious than selective COX-2
inhibition.27
While both studies were carried out in mouse models, the COX pathway and the
COX-dependent inflammatory signature is remarkably conserved in humans. In addition
to mouse models, scientist also examined human biopsy samples from cutaneous
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melanoma and found very similar mRNA expression levels of tumor promoting
cytokines.27
While the previous studies were carried out mainly in murine models, the same
principles have been demonstrated using human tissue cultures. Combined PD-1
blockade and disruption of COX-2 signaling lead to the eradication of tumors and
increased the number of tumor-specific cytotoxic T lymphocytes (CTLs). Furthermore,
the study showed that tumor-derived prostaglandin E2 (PGE2) plays an important role in
depressing CTL function.56
Clinical evidence for the synergistic effect of aspirin (a COX-1 and COX-2
inhibitor) and immune checkpoint blockade comes from the analysis of data collected in
two large prospective cohort studies.60 Hamada and colleagues examined data collected
using questionnaires and analyzed tumor samples from the participants of the Nurses’
Health Study that followed 121,701 women and Health Professional’s Follow Up study
that included 51,529 men. 621 records were chosen for analysis based on the availability
of tumor samples, data of PD-L1 expression level measured by immunohistochemistry
and aspirin use. Patients were observed from 1976 and 1986 respectively, to death or
January 1st 2012, whichever came first. Regular aspirin use was defined as either
standard-dose or low-dose, or both taken two or more times per week. Postdiagnosis aspirin use with colorectal cancer–specific survival differed by PD-L1 (CD274)
expression status (Pinteraction < .001) and overall survival (P=0.004) compared with aspirin
nonusers. In patients with low PD-L1 expression, the multivariable-adjusted hazard ratios
(HR) for regular aspirin users were 0.16 (95% CI, 0.06 to 0.41). Patients with high level
of PD-L1 expression did not seem to benefit from post-diagnosis aspirin use (P=0.85, HR
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1.01 95% CI 0.61 to 1.67). Of note, this differential prognostic association of aspirin use
and PD-L1 expression status seemed consistent among MSS and MSI-H colorectal
tumors. A weakness of this study was that chemotherapy regimens were not available for
most participants. Although data collected on the patients who did have available
chemotherapy descriptions, post-diagnosis aspirin used was not associated with
chemotherapy use, the use of different regimens could introduce a confounder.
We were interested in the dose-response relationship of which we could model our
aspirin experimental arm. Unfortunately, secondary analysis was lacking statistical power
to establish a dose-response relationship, although there seemed to be a prognostic
association by PD-L1 expression status.
In summary, while this study followed patients who underwent cytotoxic
chemotherapy or received no treatment and did not include patients whom underwent ICI
therapy, it reveals an important association between the efficacy of post-diagnosis aspirin
use and PD-L1 expression level in patients with CRC. This data points to a stratum of
CRC that will benefit from post-diagnostic aspirin use and may have very important
implications in corroborating added aspirin use in combination with ICI.
Several phase I/II trials investigating ICI + COX inhibition that are either preparing
to or are currently actively enrolling patients with various solid tumors, three of which
are carried out with colorectal cancer patients specifically or include them in their eligible
cancer type. The choice of ICI is either nivolumab or nivolumab and ipilimumab at
standard doses and aspirin at the doses 200-325mg daily or celecoxib at the doses of 200400mg daily. As these are ongoing studies, there are no published results. We will briefly
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discuss the similarities and differences in proposed rationale. See Appendix P for a
summary of these trial designs.
The current phase II study titled Nivolumab, Ipilimumab and COX2-inhibition in
Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity (NICHE)
[NCT03026140] is set out to investigate the combination of nivolumab, ipilimumab and
celecoxib as a neoadjuvant therapy in early stage CRC in both the MSS and MSI-H
subgroups. This neoadjuvant approach administers the drug combination for the short
period of 6 weeks in anticipation of shrinking the tumor prior to surgery. The regimen for
the active comparator group (Group 1) consists of a single dose of ipilimumab 1mg/kg on
day 1 and two cycles of nivolumab 3mg/kg on day 1 and 15, respectively. The
experimental group (Group 2) is given a single dose of ipilimumab 1mg/kg on day 1, two
cycles of nivolumab 3mg/kg on day 1 and 15 and 200mg celecoxib daily until the day
before surgery. While all MSI-H patients are allocated to Group 1, MSS patients are
randomized to Group 1 or Group 2. Compared to this trial design, our proposed study
will recruit CRC patients with metastatic disease that this trial excludes. Notably, we will
use a double the dose (400mg) of celecoxib proposed here. Although the study design of
neoadjuvant treatment might warrant a lower dose. Furthermore, our study avoids
randomizing MSS participants into an ipilimumab/nivolumab treatment group only that
has previously shown an inadequate response by using a cross trial comparison arm.
While our approach might have decreased validity due to slight institutional differences
in how variables are operationalized, it will expose participants to the least possible harm.
Another current Phase II study, titled PD-1 Antibody Combined With COX Inhibitor
in MSI-H/dMMR or High TMB Colorectal Cancer [NCT03638297] investigates the
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combination of nivolumab and COX inhibition in MSI-H/dMMR CRC. As mentioned
earlier, about 3% of MSS lesions are high TMB (tumor mutation burden), thus they
would be included in this study. This trial differs from ours in that it restricts its
participants to high TMB that is generally associated with a faulty DNA repair
mechanism and adds celecoxib to modulate the inflammatory tumor environment. This
would theoretically increase the proportion of CRC that responds to ICI treatment but
continues to exclude the majority of CRC patients.
The current Phase II study titled An Open Label Phase II Study Combining
Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors (NICECOMBO) [NCT03864575] investigates the combination of nivolumab and celecoxib in
late stage solid tumors. Although this study did not specify CRC as an eligible cancer
type, the characteristics of the cancers treated, e.g. “cold”, “advanced solid tumors” “with
an indication of treatment with anti-PD1 antibodies” technically include MSI-H mCRC,
for which the nivolumab/ipilimumab combination is FDA approved. This trial is similar
to ours in that it aims to treat “cold” tumors.
The phase Ia/Ib trial investigates safety in a dose escalation of radiation 0.5-3Gy in
addition to a fixed ICI and proposed immunomodulatory regimen (aspirin,
cyclophosphamide) dose. The ipilimumab/nivolumab regimen is combined with a 300mg
daily aspirin dose and cyclophosphamide. This is the only Phase I study examining ICI
plus immunomodulation, due to the radiation dose escalation component, while the drug
doses remain fixed.
The Phase II study titled PRIMMO aims to treat refractory cervical and endometrial
cancer using a combination of radiation, ICI (pembrolizumab) and immunomodulation
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(Vitamin D, aspirin, cyclophosphamide and lansoprazole). The aspirin dose used was
325mg daily. This study also examines the combination of ICIs and immunomodulation
including aspirin in a stage IV solid tumor type.
In conclusion, there is mounting evidence to support translational continuation of
pre-clinical work with ICI and COX inhibition combination.
2.3 REVIEW OF POSSIBLE CONFOUNDING VARIABLES
There are well-studied prognostic markers that pertain to the general CRC population.
The prognostic markers within the MSS mCRC population are less well studied,
especially regarding to ICIs treatment. In this section, we will discuss prognostic markers
as they pertain to confounding study data.
The general prognostic markers of CRC are lymph node involvement, presence of
metastases, right- versus left-sided tumor, microsatellite instability (MSI-H)/deficient
mismatch repair (dMMR) vs. microsatellite stable (MSS)/proficient mismatch repair
(pMMR), KRAS, BRAF and NRAF mutation status.10 As we will be restricting our study
population to MSS metastatic CRC, the known prognostic markers that remain as
possible confounders are right- versus left-sided tumor, KRAS, BRAF and NRAF
mutation status. KRAS confers poor prognosis in the MSS CRC according to the
guideline from the American Society for Clinical Pathology, College of American
Pathologists, Association for Molecular Pathology, and American Society of Clinical
Oncology, thus it will be considered a confounder.
Myelosuppression is a known adverse event associated with chemotherapeutic
agents10 that is theoretically a negative predictor of ICI therapy response, although not
well studied in CRC. Thus, previous and especially recent cytotoxic chemotherapy might
be a negative predictor of response and a confounder.
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Right- versus left-sided tumor was found to be a strong prognostic marker of survival.
A large meta-analysis and systematic review of 1,347 846 patients found that left sided
primary tumor location was associated with a markedly reduced risk of death (HR, 0.82;
95% CI, 0.79-0.84; P < 0.001) independently of stage, race, use of chemotherapy, year of
study (1995-2016), number of participants and quality of study.61 While this study did not
perform a sub-group analysis based on MSI status and didn’t explore ICI use, its results
must be considered. As a strong prognostic predictor in the general CRC population, the
location of the primary tumor should be considered a confounder and be factored into the
final data analysis.
Age and sex were both found to be prognostic factors specifically for ICI use.62
Increased age is associated with immunoscenescence that leads to decreased lymphocyte
function and exhaustion of T-cell function.63 Male patients seem to respond better and
demonstrate significantly increased survival when treated with ICI therapy, but the role
of sex in this phenomenon is largely unknown.62
Another strong prognostic predictor specifically in the mCRC population we will be
restricting is the presence of brain or leptomeningeal metastases. While a rare type of
metastases with an incidence in CRC are 0.6-3.2%, 64 it is a strong prognostic predictor of
morbidity and mortality. The median survival after brain metastases diagnosis is 2.6- 7.4
months64, compared to any distant metastases that are associated with a median survival
of approximately 20 months.65 Due to its paucity, restriction of brain metastases will not
likely to have a significant effect on external validity, while increasing internal validity.
In summary, we will take several precautions in treating variables that can have an
effect on the outcomes in our study. We have restricted some variables, such as brain
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metastases, that were rare enough to pose threat to the external validity. Possible
confounders discussed here and proposed mediators discussed in Section 2.4i will all be
considered in the post-trial exploratory analysis.
2.4 REVIEW OF METHODOLOGY
This section will provide evidence to support methodology proposed in this study. Please
refer to Chapter 3 for detailed description of methodology and study protocols.
2.4a Study Design
The proposed study will be a single-center, open label, Phase II exploratory study
with randomized parallel assignment of two arms investigating the effects of
nivolumab/ipilimumab + celecoxib or aspirin compared to nivolumab/ipilimumab alone
in patients with MSS/pMMR mCRC. We will report efficacy, safety, biomarker
association and patient reported outcomes (PRO) in both MSS/pMMR cohorts. All
participants will receive the same weight-based dose nivolumab/ipilimumab + fixed
dose celecoxib or aspirin regimen. The MSS/pMMR cohort will not receive the
nivolumab/ipilimumab only regimen due to the low objective response rate (2/23) and
short PFS (1.4 months) observed in this cohort in the CheckMate 142 trial.4 The mean
PFS associated with the current standard of care therapy of regorafenib is 3.34 months
and the associated response rate is 2%.12 The MSS/pMMR cohort will be compared to
historical control of the CheckMate 142 MSS/pMMR cohort with an identical ICI
regimen in combination with COX inhibition and comparable follow up time. This
cross-trial comparison will allow for sparing the MSS/pMMR cohort from being
randomized into a treatment group that has shown less than optimal results previously.
Although each treatment component separately has well known and tolerable
safety profiles, our aim is to closely monitor the safety of the combination treatment.
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2.4b Patient Selection and Study Population
This study will compare two single treatment arms to the historical control of the
CheckMate 142 study MSS cohort and will use the same patient selection criteria to
increase the validity of this cross-trial comparison.4 This study will recruit adults of age ≥
18 years with histologically confirmed distant metastatic spread of CRC (Stage IV as
defined by TNM staging criteria), confirmed MSS/pMMR genotype who has progressed
on previous treatment with cytotoxic chemotherapy using fluoropyrimidine, oxaliplatin
and irinotecan. In the CheckMate 142 study, the restriction of previously treated patients
was necessary to conform to the FDA approved indication for the low dose ipilimumab
and nivolumab combination, although patients who declined the use of chemotherapeutic
agents were included. In this study, we are using this regimen for a population (MSS
mCRC) for whom it is not FDA approved, but will keep the restriction of previous
treatment to increase the validity of the cross-trial comparison. The population of interest
will have ECOG performance status of 0 or 1, evaluated within one month before
randomization.
The exclusion criteria include high dose prednisone (> 10mg daily dose) required for
autoimmune disease. As prednisone reverses the effect of ICIs, it would dampen
treatment effect. Patients with prior treatment with the anti-PD1, anti-PD L1/L2 and anti
CTL-4 immune checkpoint or other agent targeting T-cell co-stimulation or immune
checkpoint pathways are excluded from this study. Patients with serious uncontrolled
medical disorders are also excluded, as these confounding disorders would affect
morbidity and mortality. Some organ function parameters are also dictated by the added
aspirin or celecoxib treatment, as these medications are contraindicated for patients with
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acute or severe hepatic or renal failure or bleeding diatheses.66 Patients must demonstrate
adequate organ function as defined in Appendix O.
Patients must have a lesion that is accessible for a biopsy or has had a biopsy with
accessible tissue in the past 6 months and the patient is willing to provide this tissue for
study purposes.
Patients with brain metastases will be excluded from this study. Brain metastases are
rare in the CRC population. A systematic review found that the incidence of brain
metastases in CRC are 0.6-3.2%.64 They, however, carry increased mortality and
morbidity. The median survival after brain metastases diagnosis is 2.6- 7.4 months64
compared to about 20 months with any metastases65 and thus brain metastases diagnosis
must be excluded from our study as a potential confounder.
Patients must not be taking Non-steroidal Anti-inflammatory Drugs (NSAIDs),
aspirin or COX-2 inhibitors at the time of registration and they must not have a
documented allergic reaction or hypersensitivity to them. Aspirin is a non-reversible antiplatelet drug, which is also contraindicated for patients with bleeding diatheses. Patients
with bleeding diatheses will also be excluded due to the increased bleeding risk. Patients
with a history of peptic ulcer disease or gastrointestinal bleeding will be excluded from
the study due to the increased risk of bleeding seen with NSAIDs, especially aspirin.66,52
Female participants must not be pregnant or breastfeeding and both sexes must agree
to use effective contraception for the duration of the study and up to 90 days after the last
study drug administration.
Refer to Appendix E for ECOG Performance Status Criteria. Please see Appendix B
form MSI criteria and testing options. Of note, the three MSI testing options are deemed
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to be equally effective thus there is no specific testing option is recommended by the
FDA.17 Please see the criteria for TNM staging in Appendix A and the RECIST criteria in
Appendix K.
2.4c Dosing Regimen of Nivolumab and Ipilimumab
The FDA approved dosage of nivolumab and ipilimumab for MSI-H/dMMR CRC is
nivolumab 3 mg/kg followed by ipilimumab 1 mg/kg on the same day every 3 weeks for
4 doses, then nivolumab 240 mg every 2 weeks until disease progression or unacceptable
toxicity. This regimen was determined based on safety data from the CheckMate 142
trial.4
FDA dosage recommendations were revised in March 2019 to a non-weight-based
regimen as follows: Adult and pediatric patients ≥40 kg: 240 mg every 2 weeks or 480
mg every 4 weeks. Adult and pediatric patients ≥40 kg: 3 mg/kg followed by ipilimumab
1 mg/kg on the same day every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480
mg every 4 weeks.67
The recently revised Opdivo (nivolumab) package insert advises 30 minute infusion
times, however, in the CheckMate 142 study the drug infusions of nivolumab took place
over 60 minutes and the infusions of ipilimumab took place over 90 minutes, thus we will
be using this infusion timeline as well as the dosing regimen to keep study parameters
identical increase the validity of the cross-trial comparison.
2.4d Dosing Regimen of Celecoxib
The fixed dosing regimen of celecoxib was determined based on safety data and the
intent of providing the highest dosage with tolerable toxicities to avoid sub-therapeutic
treatment dosages. The 400mg once daily regimen was based on safety data obtained in a
meta-analysis that examined celecoxib doses in secondary chemoprevention in CRC
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patients.46 Celecoxib safety is discussed further in Section 2.2g. There will be no dose
adjustments made to keep study variables consistent.
2.4e Dosing Regimen of Aspirin
As the highest dose of aspirin that is effective in producing a synergistic effect with
ICIs is not known, the dose of aspirin was also determined based on safety data. Our
intent was to use the highest tolerable dose to avoid subtherapeutic dosages. We will use
the 325mg daily dose based on safety data discussed in Section 2.2g. No dose
adjustments will be made to keep study variables constant.
2.4f Intervention
The intervention consists of celecoxib or aspirin that will be administered in addition
to the nivolumab plus low dose ipilimumab combination. The timing, mode of
administration and dose of nivolumab and ipilimumab will be modeled after the
CheckMate 142 trial to ensure increased validity of the cross-trial comparison. The
celecoxib and aspirin doses were determined based on safety studies referenced in
Section 2.4d and 2.4e as there are no safety or efficacy data from clinical trials regarding
the combination of COX inhibitors and ICIs.
2.4g Primary Outcome Measures
The primary outcome measure will be objective response rates (ORR) radiologically
examined and evaluated by the RECIST v1.1 criteria.
Refer to SUPPLEMENT Q for definitions of outcome measures as per RECIST v1.1.
This outcome measure was chosen to match the CheckMate 142 trial to ensure the
validity of the cross-trial comparison.
2.4h Secondary Outcome Measures
The secondary outcome measures were also chosen to match the secondary
outcomes of the historical control of the CheckMate 142 trial, except for the blinded
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independent central review (BCIR) ORR and PFS, as our study is a single center study
and does not require central review. Secondary endpoints are disease control rate (DCR),
progression free survival (PFS), overall survival (OS), safety and tolerability, association
between biomarker expression (BRAF mutation status, KRAS mutation status, PD-L1
expression, clinical history of Lynch syndrome) and efficacy and changes from baseline
in patient reported outcomes (PRO).
The patient reported outcomes (PRO) will consists of two questionnaires. These
will be conducted at baseline, and at every 6 weeks based on the European Organisation
for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire
(QLQ-C30) and three-level five-dimensional EuroQol instrument (EQ-5D). The EORTC
QLQ-C30 has three components: symptoms, functioning and quality of life (QOL). The
EuroQol instrument is a non-disease specific questionnaire that is intended to
complement the QLQ-C30 that was designed to evaluate quality of life measures in
patients participating in clinical studies.68,69,70
2.4i Other Variables
Although there are no validated independent prognostic predictors of survival or
response specifically in MSS mCRC regarding ICI treatment, there are several promising
emerging biomarkers such as Immunoscore and MDSC level.
Immunoscore is a novel cancer classification system with a focus on immune
infiltration in the tumor microenvironment. The Immunoscore system sums up the
density of CD3+ and CD8+ T-cell effectors both within the tumor and within the invasive
margin, scored 0 (no T-cell effectors in either tumor or invasive margin) to I4 (T-cell
effectors in both tumor tissue and invasive margin).
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There is accumulating evidence that Immunoscore could be predictive of ICI efficacy
in both the MSS and MSI-H populations. In fact, a multivariate analysis showed that
Immunoscore is a stronger predictor of patient survival and disease specific recurrence
than microsatellite instability.71
An international consortium conducted a study to assess the prognostic value of
Immunoscore found that in TNM stage I-III colorectal cancer, Immunoscore association
for time to recurrence was independent of patient age, sex, T stage, N stage,
microsatellite stability and other existing prognostic factors studied.21 The study that
examined tissue samples from 3539 patients also found significant positive correlation
between densities of CD3+ and CD8+ tumor cells and survival and negative correlation
with the risk of recurrence. The difference in risk of recurrence reported as hazard ratio
(HR) in high vs. low Immunosocre was 0.20, (95% CI 0.10-0.38; p<0.00010) translating
to an 80% reduction in recurrence risk.21 Of significance, 21% of patients with MSS
colorectal tumors have high Immunoscore21 and about 50% had I3-I4.71 Thus, it is
possible that Immunoscore could identify a subset of MSS CRC that can be targeted with
immunotherapies. Altough Immunoscore was found to be a more effective predictor than
age and sex, the results have not been validated for mCRC (only TNM stage I-III), thus
age and sex will have to be considered as factors for stratification in the mCRC
population in our study.
A negative predictor of survival is MDSC level. Importantly, MDSCs found in the
blood stream predict higher TNM stage and increased mortality,72 thus it is a useful
marker of survival. A meta-analysis found cancer mortality doubled upon the detection of
MDSCs with associated HR for OS, 1.94; 95% confidence interval [CI], 1.42-2.66; P <
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0.0001) in patients with solid tumors, including CRC.73 Since increased COX-2
expression leading to increased PGE2 levels may be one mechanism that allows tumor
cells to evade host immune surveillance through accumulation of myeloid-derived
suppressor cells (MDSCs) and evasion from T cell–mediated immune attack, we
anticipate that MDSC level be a better marker of objective response rate than COX-2
expression level. Thus, instead of COX-2 levels, we will use its downstream effector
MDSC as a stratum for random allocation.
Of note, Immunoscore and MDSC level are both hypothesized to be in the CRC
causal pathway, thus are considered to be mediators rather than confounders.
Biomarker assessment will include genotyping the oncogenes KRAS, NRAF, BRAF
(mutated vs. wild type), clinical history of Lynch syndrome, tumor PD-L1 expression
level, tumor burden and COX-2 expression. We will measure MDSC levels and Creactive protein as a novel marker of chronic inflammation, as well as the immune
suppressive cytokines sTNF, Il-1β, Il-10 and TGF-β.
The CheckMate 142 trial did not find any association between objective response
rates in MSI-H/dMMR mCRC and history of Lynch syndrome, BRAF or KRAS mutation
status or PD-L1 expression status4. These associations, except for no association of
responses with PD-L1 expression status, were not reported and perhaps would not have
been statistically meaningful in the small (23 patients) MSS/pMMR population examined
in their trial. In this study we aim to recruit a larger sample of MSS patients to direct us
toward more clinically meaningful data on biomarker association with objective response
rate within the MSS/dMMR population.
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2.4j Sample Size and Statistical Significance
Simon’s two-stage design will be used. The primary objective of phase II trials is to
determine whether the intervention (here a drug combination) has sufficient activity
against a disease state, which here is MSS mCRC. In a traditional single stage study
design, this determination could take months or years, exposing patients to treatments
that might have no benefit for them, and might even expose them to undue risk. The goal
of the Simon’s two-stage design is to minimize sample size in case the intervention has
low or no activity.74
In the first stage, 14 patients will be enrolled. If there are 1 or fewer responses in
these 14 patients, the study will be stopped. Otherwise, 27 additional patients will be
enrolled for a total of 41. The null hypothesis will be rejected if 7 or more responses are
observed in 41 patients. This design yields a type I error rate of 5% when the true
response rate is 23.7%. Refer to Appendix N for more information.
2.5 CONCLUSION
Several lines of evidence have shown that the combination of checkpoint inhibition
and COX-2 inhibition act synergistically to reduce tumor promoting inflammation and
increase immunogenicity in the tumor environment. The success of checkpoint inhibition
via the combination of PD-1 blockade and COX-2 inhibition in preclinical studies using
murine and human in vitro models suggests a possible role for this combination therapy
in the treatment of mCRC in the clinic. The association of lower PD-L1 expression and
survival in post hoc analysis of large prospective cohort studies further strengthens the
case for the addition of COX inhibitors as an immunomodulatory agent to ICIs for the
treatment of MSS CRC, that historically responds poorly to ICI treatment.
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2.6 DEFINITIONS
KRAS: Kirsten Rat Sarcoma gene. Oncogene that normally controls cell proliferation.
Mutated KRAS confers unchecked cell proliferation.
NRAS: Neuroblastoma Rat Sarcoma gene, proto-oncogene.
BRAF: Murine oncogene viral sarcoma Homolog B, a proto-oncogene
Interferon ϒ+ A cytokine that functions in immune processes
Tregs Tumor-infiltrating regulatory T-cells
Interleukin 6,8 and 1 tumor promoting cytokines
CTLs Cytotoxic T lymphocytes, lymphocytes responsible for attacking viral invaders and
cancer cells or other damaged cells
CD247 A gene that encodes programmed death ligand one (PD-L1)
Mlh1 and Msh2 mismatch repair genes often mutated in the MSI-H phenotype
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CHAPTER 3: STUDY METHODS
3.1 STUDY DESIGN
The proposed study will be a single center, open label, randomized allocation, parallel
assignment, Stage II clinical trial investigating the effects of nivolumab/ipilimumab plus
celecoxib or aspirin in patients with MSS/pMMR mCRC compared to a historical control
of nivolumab/ipilimumab alone in MSS/pMMR mCRC arm of the CheckMate 142 trial.
Assignment to the celecoxib or aspirin treatment group will be determined by random
assignment. We will also follow the biomarkers BRAF/KRAS/NRAS mutation status (at
baseline), PD-L1 expression, IDO1 expression, MDSC level and COX-2 expression
level, cytokines Il-6 and Il-1β evaluated at baseline and at the follow up biopsy.
3.1a Study Groups
Our interventional groups consist of patients who are ≥ 18 years of age and have
mCRC that is histologically confirmed as MSS or pMMR mCRC, evaluated by local
guidelines. (See Appendix B for MSI criteria evaluation options.) These patients either
have progressed on or were intolerant of previous treatment with cytotoxic chemotherapy
with irinotecan, fluorouracil and oxaliplatin. Patients who declined systemic
chemotherapy are also eligible. Patients are permitted to have participated in curativeintent or palliative radiation therapy, chemotherapy, biological therapy or other
investigational therapy but all therapies must be completed by >28 days before treatment
initiation and all palliative radiation treatments must be completed ≥ two weeks before
treatment initiation. All patients must have an Eastern Cooperative Oncology Group
(ECOG) performance status of ≤ 1 and measurable disease per Response Evaluation
Criteria in Solid Tumors (RECIST version 1.1). See Appendix E for ECOG performance
status and Appendix K for RECIST criteria classifications.
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Exclusion criteria includes any active, known or suspected autoimmune disease,
requiring corticosteroid treatment >10mg prednisone daily or other immunosuppressive
medication ≤ 14 days prior to beginning treatment. Patients with prior treatment with the
anti-PD1, anti-PD L1/L2 and anti CTL-4 immune checkpoint or other agent targeting Tcell co-stimulation or immune checkpoint pathways are excluded.
Also excluded are patients with serious uncontrolled medical disorders. Patients with
active brain or leptomeningeal metastases or prior malignancy within the previous 3 years
except for cured select localized cancer are also excluded from the study.
Patients must not be taking Non-steroidal Anti-inflammatory Drugs (NSAIDs),
Aspirin or COX-2 inhibitors at the time of registration and they must not have a
documented allergic reaction or hypersensitivity to them. Patients with a history of peptic
ulcer disease or GI bleeding are excluded. Patients with bleeding coagulopathies, such as
Von Willebrand disease, liver failure, antiphospholipid syndrome, glucose-6 phosphate
dehydrogenase (G6PD) deficiency, and hemophilias will be excluded from the study.
Female participants must not be pregnant or breastfeeding and both sexes must agree
to use effective contraception for the duration of the study and up to 90 days after the last
study drug administration.
3.1b Treatment Administration
Nivolumab will be dosed at 3mg/kg IV, administered over 60minutes followed by
ipilimumab 1mg/kg IV infusion administered over 90minutes once every 3 weeks for
four doses and then nivolumab 3mg/kg IV once every 2 weeks until disease progression,
discontinuation because of toxicity, death, withdrawal of consent, or study end. No dose
modifications are permitted. See Appendix H for Nivolumab and Ipilimumab dose
calculations. Dose interruptions due to treatment related adverse events (TRAEs) are
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permitted and documented. See Appendix M for Criteria for Treatment Delay and
Resumption. Treatment beyond the initial progression will be permitted if the patient
tolerates and deemed to benefit from the study treatment at the investigator’s discretion.4
3.2 PATIENT SELECTION AND STUDY POPULATION
The source population includes adults of at least 18 years of age with previously
treated microsatellite stable (MSS) mCRC. The study population is drawn from this pool
over a 6-month enrollment period at Yale New Haven Hospital. All participants must
have a completed eligibility criteria checklist (Appendix F Eligibility Criteria Checklist).
The eligibility criteria are described in detail in Section 3.1. After confirmation of
eligibility, signing of the Consent for Participation in the Research Project (Appendix G)
by both the patient and the investigator and completing the Patient Registration Form
(Appendix I), the patients will be assigned an identifying number (Patient Registration
Number) by a regulatory staff member. This identifying number will be recorded on
every document in addition to the patient’s name and serve as a patient identifier.
3.3 STUDY REGULATION AND SUBJECT CONFIDENTIALITY
Yale cancer trials are sponsored by the National Cancer Institute (NCI) and follow
NCI guidelines outlined in the Investigator’s Handbook.75 The protocol application along
with the Compound Authorization and Consent for Participation in a Research Study
form (Appendix G) will be submitted to the Yale Institutional Review Board (IRB). All
study personnel will obtain Health Insurance Portability and Accountability Act (HIPAA)
certification prior to the beginning of recruitment. Research staff must also complete the
Yale HIC training. Although all four drugs used in the trial are commercially available,
because they are used off label, the study will be required to file the investigational new
drug (IND) form with the FDA. The study protocol and amendments will be approved by
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the Yale Human Investigation Committee (HIC). The study will be conducted in
accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, and
the informed consent form that explains the study in an easily understandable language
will be supplied to eligible participants.
3.4 RECRUITMENT
Study participants will be recruited from the pool of patients undergoing treatment for
mCRC at Yale Cancer Center (YCC), which is a National Cancer Institute (NCI)
designated comprehensive cancer center in Southern Connecticut. YCC is a collaboration
between nationally and internationally renowned researchers, physicians, physician
assistants, nurse practitioners and medical staff at the Yale School of Medicine and
Smilow Cancer Hospital. Participants will be recruited from the YCC group sites over a 6
months period via flyers and advertisements placed on clinical trial websites.
3.5 STUDY VARIABLES AND MEASURES
The independent variables of the study are the drug regimen used in the two arms of
the study. Arm A will be given ipilimumab 1mg/kg IV, nivolumab 3mg.kg IV and aspirin
325mg daily orally, while Arm B will be given ipilimumab 1mg/kg IV, nivolumab
3mg/kg IV and celecoxib 400mg daily orally. The dependent variable examined as the
primary outcome is objective response rate (ORR). ORR is defined as best response or
complete response (CR) or partial response (PR) divided by the number of treated
patients as per RECIST v1.1 guideline. To determine the ORR, tumor burden will be
measured at baseline and throughout the treatment period. Secondary endpoints
(dependent variables) were disease control rate (DCR), safety and tolerability,
progression free survival (PFS), overall survival (OS), association between biomarker
expression (COX-2 expression level, MDSC level, PD-L1 level, C-reactive protein level,
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cytokine Il-1β and Il-6 expression) and efficacy (ORR, PFS, OS) and changes from
baseline in patient reported outcomes (PRO). Secondary outcome measures will also be
measured at baseline and followed throughout the study, as discussed in Section 3.7.
3.6 METHODOLOGY CONSIDERATIONS
3.6a Assignment of intervention
Upon the completion of the eligibility checklist and registration form, the patients
will be randomly assigned using permuted block randomization to either study Arm A or
B of by a statistician. Neither patients, nor research staff will be blinded to allocation.
3.6b Adherence
Adherence will be monitored and recorded throughout the duration of the study.
Study medications administered by the treatment team such as nivolumab and
ipilimumab infusions will be logged at each visit. Patients will be reminded of infusion
appointments via telephone 24 hours prior to the appointment time and will require a
verbal confirmation. Patients will be given the oral medications in study issued bubblepackaging with dates for each dose and patients will be required to return the empty
packaging at the subsequent appointment time. Adherence to oral medication will be
logged by Research Staff.
3.6c Monitoring of Adverse Events
All adverse events (AEs) will be reported to the Yale IRB at the time of the
continuing review. Serious adverse events (SAE) will be reported to the Yale IRB within
5 business days using the Form 710 FR4: UPIRSO, Including AEs Reporting Form
through the Yale IRES (See Appendix Q for definitions of AE and SAE).76
Adverse events will be further analyzed based on the published in-depth safety
evaluation of the CheckMate 142 trial24 and will include frequency of treatment related
adverse events (TRAEs), select TRAEs (sTRAEs), and immune related adverse event
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incidences, time to onset (TTO), time to resolution (TTR), immune modulating
medication (IMM) use, dose delay, and sTRAE occurrence after resuming therapy. Refer
to Appendix N for definitions of TRAE and IMAE (Immune mediated adverse events).
3.7 DATA COLLECTION
Efficacy and safety data will be collected on any patient who received at least one
treatment dose. The data will be collected by the study Research Staff and by
administrative staff at Smilow Cancer Hospital at Yale. Subjects will be enrolled during a
six months enrollment period and the data collection phase will take 18 months for the
total study duration of two years.
Tumor burden will be measured at baseline using computed tomography (CT) or
magnetic resonance imaging (MRI) evaluated by the RECIST criteria (Version 1.1) ≤ 28
days before the first dose (Treatment Start Date). Subsequent assessments will be carried
out every 6 weeks for 24 weeks and every 12 weeks thereafter until either disease
progression or discontinuation. All responses will need to be confirmed by a second scan
≥ 4 weeks later. The primary endpoint of objective response rate (ORR) will be based on
these imaging studies. Patients will be observed for survival every three months up to the
two-year mark of the study to evaluate the secondary endpoint of overall survival (OS).
Patient reported outcome (PRO) analyses will be conducted at baseline, and at every
6 weeks based on the European Organisation for Research and Treatment of Cancer
(EORTC) Core Quality of Life Questionnaire (QLQ-C30) and three-level fivedimensional EuroQol instrument (EQ-5D).69, 68
The EORTC QLQ-C30 has three components: symptoms, functioning and quality of
life (QOL), each using a scale of 0-100, with 100 corresponding to the best functioning
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and 0 corresponding to the worst functioning. For each of these scales an at least 10-point
change from baseline was deemed clinically meaningful.70
The EQ-5D will analyze problems in five health dimensions: mobility, self-care,
usual activities, pain or discomfort, and anxiety or depression and will rate them on a
scale of “None”, “Some” or “Extreme”. We will also utilize the EQ-5D visual analog
scale that patient will use to rate their health on a scale of 0-100, with higher values
corresponding to better health. An at least 7-point change from baseline will be regarded
as clinically meaningful.
Participants will be assessed for signs and symptoms of ICI related adverse events
and blood samples will be collected at baseline and before each ICI dose to evaluate
clinical chemistries including liver function tests (LFTs), adrenocorticotropic hormone
(ACTH) level, and thyroid function tests.
Tissue samples will be collected from all participants. Patients will be able to provide
data from a previous biopsy to determine the baseline biomarker status but a second
sample will be collected to determine changes from baseline. Tissue samples will be
collected according to the Yale IRB Policy 440: Collection and Banking of Data,
Biological Specimens and Other Materials in Human Research.77
Safety will be evaluated using the Common Terminology Criteria for Adverse Events
(CTCAE Version 5.0 See Appendix D) throughout the duration of the treatment.50
3.8 SAMPLE SIZE CALCULATION
Simon’s two-stage design will be used.74 The null hypothesis that the true
response rate is 8.7% observed in the CheckMate 142 trial will be tested against two onesided alternatives. In the first stage, 14 patients will be enrolled. If there are 1 or fewer
responses in these 14 patients, the study will be stopped. Otherwise, 27 additional
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patients will be enrolled for a total of 41. The null hypothesis will be rejected if 7 or more
responses are observed in 41 patients. This design yields a type I error rate of 5% when
the true response rate is 23.7%. See Appendix J for additional calculations.
3.9 ANALYSIS
Data analysis will be modeled after the CheckMate 142 trial. The baseline
demographics data such as age, sex, race, ECOG performance status, primary tumor
location, number of prior systemic treatments, prior therapies received, prior radiotherapy
received, mutation status (BRAF/KRAS wild type, BRAF mutation, KRAS mutation,
unknown), tumor PD-L1 expression quantifiable at baseline and clinical history of Lynch
syndrome of the study sample will be described and compared by treatment group and
historical control group. The data will be reported using descriptive statistics with
standard deviation and means, medians and ranges for continuous variables.
Data from all enrolled patients will be analyzed regarding efficacy and safety. The
secondary outcomes of safety and tolerability and patient reported outcomes (PRO) will
also be measured using descriptive statistics. The 95% CI for the dichotomous measure of
objective response rates (ORR) will be estimated using the Clopper and Pearson method.
ORR (proportion of patients with a predefined amount of tumor reduction) in the two
treatment arms will be compared using the chi-square test. If the observations are rare,
Fisher Exact Test will be used. The Kaplan-Meier product-limit method will be used to
determine medians for time to event measures such as progression-free survival (PFS),
overall survival (OS), duration of response (DOR) and the corresponding 95% CI will be
calculated based on log-log transformation.
The primary outcomes of objective response rate (ORR) and the secondary
outcomes of disease control rate (DCR), progression free survival (PFS), overall survival
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(OS) will be measured based on the RECIST v1.1 guideline. Data will be analyzed based
on the per protocol analysis. We will consider P-values less than 0.05 as statistically
significant for all analyses.
3.10 TIMELINE AND RESOURCES
The study time period is planned to be 24 months, with a 6-month period of rolling
enrollment followed by 18 months of treatment administration. Statistical analysis or
objective response rate will be performed on a rolling basis, but majority of the data
analysis will take place after the conclusion of the treatment of the last participant.
The full-time study personnel will include the principal investigator (PI), Dr. Michael
Hurwitz, Co-PI, Angela Preda, PA-SII, Research Staff (administrative) who will be
tasked with patient recruitment, data collection, and data entry. The study will seek to
recruit part time pathologist to assist with analysis of tumor samples and a statistician to
aid with data analysis. Standard oncological care will be provided by the patients’
oncologist at Yale New Haven Hospital who will have frequent communication with the
study research personnel. All clinical tasks such as phlebotomy, imaging and laboratory
analysis will be performed by hospital resources.
The full-time personnel will require office space in the Oncology Department at Yale
New Haven Hospital equipped with a computer with appropriate software for statistics,
data storage and analysis.
The study drugs ipilimumab and nivolumab will be supplied by Bristol-Myers Squibb
and Celebrex will be supplied by Pfizer Inc. No other resources will be utilized from
these pharmaceutical companies.
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CHAPTER 4: CONCLUSION
4.1 Study Advantages
Although our Phase II study sample is smaller than a Phase III trial’s, we aimed to
reduce the effect of confounders by the randomization of subjects into the two arms.
The use of a cross-trial control arm intended to reduce potential harm to subjects
by eliminating randomization to an arm with suboptimal response rates and response
durations. This trial design also reduced the number of subjects need to be recruited.
The Simon’s two-stage design introduces an element of safety as the trial will only go
to second stage if there are adequate number of responding patients. This practice avoids
exposing patients to undue risk in case the intervention has low or no activity.
The relative ease of recruitment is another advantage. The low prevalence of the MSIH mCRC forced the CheckMate 142 trial to be carried out as a multi-center study. With
96% of mCRC being MSS,6 our study anticipates greater ease in recruiting. Given the
21% prevalence of mCRC is in the CRC population, the MSS mCRC portion of all CRC
patients presenting is about 20%. Thus, theoretically, one fifth of all Yale New Haven
Hospital CRC patients are eligible to participate.

4.2 Study Limitations
To reduce the possibility of confounders, we used restriction and randomization
during the design phase of the study while also keeping the external validity in mind.
The study has moderately permissive exclusion criteria, a practice that could lend
itself to introduction of confounders. For example, previous treatment with biological or
other investigational treatments were not a reason for exclusion. As we are uncertain of
the long-term effects of these treatments, we cannot rule out them out as confounders.
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Although more strict restriction would have increased internal validity, it would have
decreased the external validity and generalizability.
Comparing the treatment arms to a historical control can also present as a drawback
since we are comparing patient populations at different institutions. For the measure of
the effect, namely objective response rate (ORR) we modeled our trial after the
CheckMate 142 study’s arm that recruited non-MSI-H mCRC patients (MSS). This arm
of the study was rather modest, recruiting only 23 patients but showed an ORR of 8.7%
(2 responses in 23 patients). Demographics and biomarker data (except for PD-L1) was
not reported for this cohort, thus we will not be able to compare the control arm and our
experimental arms regarding these variables.
While our study is designed to run for 18 months, follow up of disease recurrence at
later time points is crucial. Our 18-month study duration will be sufficient for elucidating
responses and immediate adverse events but it is essential that patients will be followed
for a longer period of time to measure long-term effects of these drugs.
Another limitation of our study is that although it permits the participation of patients
who decline the use of cytotoxic chemotherapy, the majority of patients will have had
previous treatment with one or more first or second line agents. To recruit sufficient
number of patients in a single center setting, we cannot restrict this variable. However,
the response rates might be increased in treatment naïve patients.
4.3 Clinical Significance
This trial aims provide an ICI option to the MSS subgroup, which currently relies on
traditional cytotoxic chemotherapy. Thus, an immune therapy option for this population
would signify a paradigm shift. We also anticipate gaining insight into the biomarkers
identifying future responders.
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APPENDICES

APPENDIX A TNM STAGING OF COLORECTAL CANCER

General Definition of Colorectal Cancer:
Adenocarcinoma, high-grade neuroendocrine carcinoma and squamous carcinoma of the
colon and rectum are covered by this staging system
Excluded are appendiceal carcinoma, anal carcinoma and well-differentiated
neuroendocrine tumor (carcinoid)
Stage grouping
Stage 0: Tis
N0
M0
Stage I:
T1 - T2 N0
M0
Stage IIA: T3
N0
M0
Stage IIB: T4a
N0
M0
Stage IIC: T4b
N0
M0
Stage IIIA: T1 - T2 N1 / N1c M0
T1
N2a
M0
Stage IIIB: T3 - T4a N1 / N1c M0
T2 - T3 N2a
M0
T1 - T2 N2b
M0
Stage IIIC: T4a
N2a
M0
T3 - T4a N2b
M0
T4b
N1 - N2 M0
Stage IVA: any T any N M1a
Stage IVB: any T any N M1b
Stage IVC: any T any N M1c

Primary tumor (pT)
• TX: primary tumor cannot be assessed
• T0: no evidence of primary tumor
• Tis: carcinoma in situ, intramucosal carcinoma (involvement of lamina propria
with no extension through muscularis mucosae)
• T1: tumor invades submucosa (through the muscularis mucosa but not into the
muscularis propria)
• T2: tumor invades muscularis propria
• T3: tumor invades through the muscularis propria into the pericolorectal tissues
• T4:
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o

o

T4a: tumor invades through the visceral peritoneum (including gross
perforation of the bowel through tumor and continuous invasion of tumor
through areas of inflammation to the surface of the visceral peritoneum)
T4b: tumor directly invades or adheres to other adjacent organs or
structures

Regional lymph nodes (pN)
• NX: regional lymph nodes cannot be assessed
• N0: no regional lymph node metastasis
• N1: metastasis in 1 - 3 regional lymph nodes
o N1a: metastasis in 1 regional lymph node
o N1b: metastasis in 2 - 3 regional lymph nodes
o N1c: no regional lymph nodes are positive but there are tumor deposits in
the subserosa, mesentery or nonperitonealized pericolic or perirectal /
mesorectal tissues
• N2: metastasis in 4 or more regional lymph nodes
o N2a: metastasis in 4 - 6 regional lymph nodes
o N2b: metastasis in 7 or more regional lymph nodes

Distant metastasis (pM)
• M0: no distant metastasis by imaging; no evidence of tumor in other sites or
organs (this category is NOT assigned by pathologists)
• M1: distant metastasis
o M1a: metastasis confined to 1 organ or site without peritoneal metastasis
o M1b: metastasis to 2 or more sites or organs is identified without
peritoneal metastasis
o M1c: metastasis to the peritoneal surface is identified alone or with other
site or organ metastases

Reference:
Weisenberg E. TNM staging of colorectal carcinoma (AJCC 8th edition).
PathologyOutlines.com website.
http://www.pathologyoutlines.com/topic/colontumorstaging8ed.html. Accessed July 13th,
2019.
APPENDIX B MICROSATELLITE INSTABILITY CLASSIFICATION

Testing for microsatellite instability in CRC can be accomplished via three methods:
1. Immunohistochemical staining for the complete loss of the four most common
mismatch repair (MMR) proteins: MLH1, MLH2, MSH6 and PMS2.
2. Testing the length of five specific microsatellites (BAT25, BAT26, D2S123,
D5S346, D17S250) via polymerase chain reaction (PCR). MSI-H classification is
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conferred to tumor samples with instability (defined as length variation between
normal and tumor samples)in greater than 30% of microsatellites.
3. MSIsensor which is a next-generation sequencing that evaluates a large number of
microsatellites throughout the genome.
Of note, the FDA does not recommend a specific testing methodology to establish MSI-H
status.
Reference:
Overman MJ, Ernstoff MS, Morse MA. Where We Stand With Immunotherapy in
Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity
Management. American Society of Clinical Oncology educational book. American
Society of Clinical Oncology. Annual Meeting. 2018(38):239-247.

APPENDIX C IMMUNOSCORE

Quantitative immunohistochemistry to determine te density of CD3+ and CD8+ cells (as
markers of TH1/cytotoxic memory T lymphocytes CD8 and CD45RO) in CRC tumors.
Immunohistochemistry staining of CD3+ and CD8+ is performed in two regions, CT
(center of tumor) and IM (invasive margin) and is followed by automated quantification
of whole slide sections. The Immunoscore utilizes the numeration of cells in the
CT and the IM of resected tumors to provide a score ranging from 0-4, Immunoscore 0
(“I” 0), when low densities of both cell types are found in both regions, to Immunoscore
4 (“I” 4), when high densities are found in both regions.
I0 – – – –
I 1 Hi – – –
I 2 Hi Hi – –
I 3 Hi Hi Hi –
I 4 Hi Hi Hi Hi
Current Immunoscore procedure and reagents
Procedure
Current recommended steps
Tumor selection
Block which is the most infiltrated by the immune cells and
containing the core of the tumor (CT) and the invasive margin
(IM)
Sample preparation 2 paraffin sections of 4-microns of the tumor block deposited in
deionized water on Superfrost-plus slides
Immunohistochemistry (IHC) 2 single stainings using IVD certified antibodies
Antigen retrieval
CC1 tris-based buffer pH8
Primary antibody
CD3 (2GV6, Ventana) and CD8 (C8/144, Dako)
Primary antibody
Diluent
K 004 (Clinisciences) for CD8
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Secondary reagents
Counterstaining
Autostrainer
Scanner
Digital pathology
Immunoscore
Quantification

Ultraview TM DAB (Ventana)
Hematoxillin II (Ventana)
Benchmark XT (Ventana)
NanoZoomer 2.0-HT (Hammamatsu)
Architect XD software (Definiens)
Immunoscore Plug-in (INSERM / AP-HP)

Reference:
Galon J, Pagès F, Marincola FM, et al. Cancer classification using the Immunoscore: a
worldwide task force. Journal of translational medicine. 2012;10(1):205.

APPENDIX D NATIONAL CANCER INSTITUTE COMMON
TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE) Version
5.0
Grade 1
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only;
intervention not indicated.
Grade 2
Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate
instrumental ADL*.
Grade 3
Severe or medically significant but not immediately life-threatening; hospitalization or
prolongation of hospitalization indicated; disabling; limiting self care ADL**.
Grade 4
Life-threatening consequences; urgent intervention indicated.
Grade 5
Death related to AE.
*Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the
telephone, managing money, etc.
**Self care ADL refers to bathing, dressing and undressing, feeding self, using the toilet,
taking medications, and not bedridden.

Reference:
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE)
v5.0
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Q
uick_Reference_5x7.pdf Published November 27, 2017. Accessed December 6, 2018.
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APPENDIX E ECOG PERFORMANCE STATUS SCALE
GRADE
0
Fully active, able to carry on all pre-disease performance without restriction
Restricted in physically strenuous activity but ambulatory and able to carry out
1
work of a light or sedentary nature, e.g., light house work, office work
Ambulatory and capable of all self-care but unable to carry out any work
2
activities; up and about more than 50% of waking hours
Capable of only limited self-care; confined to bed or chair more than 50% of
3
waking hours
Completely disabled; cannot carry on any self-care; totally confined to bed or
4
chair
5
Dead

Reference:
Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern
Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
APPENDIX F ELIGIBILITY CHECKLIST
The following form must be filled out completely and must be signed by both the patient
and the provider. Patients must meet all criteria to be eligible for this study.
Proposed treatment start date: _______________
1. ☐ Age ≥ 18 years of age. DOB _____________ Today’s date: _____________
2. ☐ Recurrent CRC or mCRC. Histologic confirmation _____________________
Sites of metastases__________________________________________________
3. ☐ No active brain or leptomeningeal metastases or prior malignancy within the
previous 3 years except for cured select localized cancer
4. ☐ Histologically confirmed MSS or pMMR ☐ Histochemistry or ☐ PCR or
☐ MSIsensor Date performed _______________
5. ☐ Use of previous chemotherapy regimens of irinotecan, fluoroacil or oxaliplatin
or refused chemotherapeutic agents
6. ☐ Completed curative-intent radiation therapy, chemotherapy, biological or other
investigational treatment > 28 days before treatment start date
7. ☐ Completed palliative radiation therapy ≥ two weeks before treatment start date
8. ☐ ECOG Performance Status 0 or 1
9. ☐ Measurable disease as per RECIST v1.1 criteria
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10. ☐ No active autoimmune disease or other disease requiring high dose
immunosuppression
11. ☐ No prior treatment with anti PD-1, anti-PD-L1/2 or anti-CTLA-4 immune
checkpoint agent or other agent targeting T-cell co-stimulation or immune checkpoint
pathways
12. ☐ No serious uncontrolled medical disorder
13. ☐ Not taking NSAIDs, aspirin or COX-2 inhibitors at the time of the registration.
14. ☐ No documented allergic reaction or hypersensitivity to COX-2 inhibitors,
aspirin or NSAIDs
15. ☐ No history of peptic ulcers or gastrointestinal bleeding
16. ☐ No bleeding diathesis
17. ☐ Absolute leukocyte count
≥2500 /mcL
18. ☐ Absolute lymphocyte count (ALC) ≥500 /mcL
19. ☐ Absolute neutrophil count (ANC)

≥1500 /mcL

20. ☐ Platelets

≥100,000 / mcL
≥9 g/dL or ≥ 5.6 mmol/L without
transfusion or EPO dependency (within
7 days of assessment)

21. ☐ Hemoglobin

22. ☐ No asthma exacerbated by aspirin or NSAID use
23. ☐No acute or severe hepatic failure
≤ 1.5 X ULN
24. ☐Serum total bilirubin
or
or
≤ ULN for subjects with total bilirubin
☐Direct bilirubin
levels > 1.5 ULN
≤ 2.5 X ULN OR
26. ☐AST and ALT
≤ 5 X ULN for subjects with liver
metastases
> 2.5 mg/dL
27. ☐Albumin
28. ☐ No acute or severe renal failure
29. ☐Serum creatinine
≤1.5 X upper limit of normal (ULN)
or
or
Measured or calculated
creatinine clearance
≥60 mL/min for subject with creatinine levels > 1.5 X
(GFR can also be used in place institutional ULN
of creatinine or CrCl)
30. ☐ Agrees to use effective contraception (both male and female)
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Women only:
31. ☐ Not pregnant or breastfeeding determined by β-Hcg level 72 hours prior
treatment start date

______________________________
Patient signature

Date: __/__/____

☐ All criteria met.

______________________________
Provider signature

Date: __/__/____

APPENDIX G COMPOUND AUTHORIZATION AND CONSENT FOR
PARTICIPATION IN A RESEARCH STUDY
IRB Protocol#

COMPOUND AUTHORIZATION AND CONSENT FOR PARTICIPATION IN A
RESEARCH STUDY
YALE UNIVERSITY SCHOOL OF MEDICINE
YALE-NEW HAVEN HOSPITAL
YALE-NEW HAVEN HOSPITAL: SMILOW CANCER CENTER

Study Title: Checkpoint and Cyclooxygenase Inhibition in Microsatellite Stable
Metastatic Colorectal Cancer
Principal Investigator (the person who is responsible for this research):
Dr. Michael Hurwitz, MD, PhD 20 York Street, New Haven, CT, 06510
Phone Number: (203) 400-4822
Research Study Summary:
We are asking you to join a research study.
• The purpose of this research study is to investigate how effective and how safe is a
new drug combination for the treatment of metastatic colorectal cancer.
• Study procedures will include: a screening visit, physical examination, blood testing,
biopsy of metastatic tumor site, CT or MRI imaging studies, infusion of
immunotherapy drugs and a medication taken by mouth.
• The number of visits required cannot be determined in advance. You will be required
to complete a screening visit and if you qualify for participating in the study, you will
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•
•
•
•
•

•

be receiving a dual immunotherapy infusion every three weeks for the total of four
doses followed by only one of the drug infusions every other week until we determine
that your cancer is not responding or you need to discontinue the treatment for
another reason.
These visits will take between 1- and 3.5-hours total.
There are some risks from participating in this study. You may experience side
effects that can range from uncomfortable to serious and can even lead to death
while taking the study medications.
The study may have no benefits to you. As the effectiveness of combination of
medications was not previously studied, we cannot tell if you will personally benefit
from participating in this study.
There are other choices available to you outside of this research. You may opt for
the standard of care treatment prescribed by your oncologist, participating in another
study or seek comfort measures only.
Taking part in this study is your choice. You can choose to take part, or you can
choose not to take part in this study. You can also change your mind at any time.
Whatever choice you make, you will not lose access to your medical care or give up
any legal rights or benefits.
If you are interested in learning more about the study, please continue reading, or
have someone read to you, the rest of this document. Take as much time as you
need before you make your decision. Ask the study staff questions about anything
you do not understand. Once you understand the study, we will ask you if you wish
to participate; if so, you will have to sign this form.

Why is this study being offered to me?
We are asking you to take part in a research study because you are an adult ≥ 18 years
of age who has been diagnosed with colorectal cancer that has spread to distant sites
(metastasized).
We are looking for 82 participants to be part of this research study that will take place at
Smilow Cancer Hospital at Yale New Haven Hospital.
Who is paying for the study?
This study is funded by the National Institute of Health (NIH).
Who is providing other support for the study?
Study medications ipilimumab (Yervoy) and nivolumab (Opdivo) were the generous gift
of Bristol-Myers Squibb. Celecoxib (Celebrex) was the generous gift of Pfizer.
What is the study about?
The purpose of this study is to investigate the effects of the combination of three drugs in
two separate groups, either nivolumab, ipilimumab and celecoxib or nivolumab,
ipilimumab and aspirin on colon cancer that has spread to distant organs (metastatic
colon cancer). Our study seeks to investigate whether either of these combinations are
more effective in the treatment of metastatic colorectal cancer than nivolumab and
ipilimumab alone. We also seek to investigate the safety of these drug combinations as
well as find biomarkers (specific markers found in the blood or in a tissue sample) that
can identify patients who respond well to treatment.

66

What are you asking me to do and how long will it take?
If you agree to take part in this study, this is what will happen: In order to determine
whether your participation in this study is appropriate, you will be asked to complete
medical screening visit. The testing is routine and can be completed by your medical
provider in one visit. To be considered eligible to participate in this study, you must be ≥
18 years of age and have a diagnosis of colorectal cancer that has spread to distant
sites but not to the brain or leptomeninges (the covering of the brain). All patients will
have a magnetic resonance imaging (MRI) to confirm the absence of brain metastases.
The diagnosis of colorectal cancer and distant spread must be confirmed by a tissue
sample (histologic diagnosis). You must be able to supply this sample and authorize our
trial to run tests on this sample. The tests run on this sample or previous testing must
classify you as microsatellite stable (MSS) and/or proficient mismatch repair (pMMR). If
no sample is available, you must authorize the study to collect a biopsy sample from an
available site. If there is no accessible biopsy site available, you will not be eligible to
participate in the study. Your provider will complete a full medical history to gather
information about your health, medications and allergies. Your provider will also
complete a thorough physical examination. You must have normal organ function prior
to starting this study. Your provider can assess this with routine blood work, which will
check your blood counts, kidney function and liver function. If any of these routine blood
tests are not within normal limits, you will not be eligible to participate. As part of the
blood testing, you will have blood testing for infectious diseases such as Hepatitis B,
Hepatitis C and HIV. If any of these tests are positive, you will not be able to participate
in the study.
A small blood sample will be taken for routine blood testing for electrolytes, blood
counts and to measure liver and kidney function and monitor for infection. This routine
blood testing will be repeated before each ipilimumab dose.
You will not be able to participate in this study if you were diagnosed with any
autoimmune disease that requires you to take more than 10mg of prednisone daily.
Your provider will determine if you are eligible. Your performance status will be
assessed and you can only participate if you are fully active or if you are restricted only
in strenuous activity.
You are eligible for this study if you have used chemotherapy of irinotecan,
fluorouracil or oxaliplatin previously and your cancer did not respond to this treatment or
if you did not want to use chemotherapy. Prior treatment with any immune checkpoint
therapy is not permitted. Prior radiation treatment is allowed, but must be completed by
>28 days before treatment start date and all palliative radiation (not curative intent)
treatments must be completed ≥ two weeks before treatment initiation. Prior treatment
with any checkpoint inhibitor is not permitted.
If you are a female of childbearing age, you must have documented negative
pregnancy test within 72 hours prior to the first dose of study medication. This can be a
blood or urine test and should be done in all women unless you have had your uterus
removed (hysterectomy) or are postmenopausal (no menstruation in the preceding 12
months). During the study, both female and male participants must agree to use
adequate birth control.
The size, number and location of your tumors will be assessed using
computerized tomography (CT) or magnetic resonance imaging (MRI) scan of your
chest, abdomen and pelvis. You will also have an MRI to check for tumors in your brain.
Both of these imaging studies will be performed within 28 days of starting study
protocol. An ECG will be performed to determine heart function. If your provider deems
necessary, additional imaging might be performed. The information gathered during
screening visits will be recorded on the Eligibility Checklist that will be stored in your file.
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If you decide to participate in this study and your provider determines that you
are eligible, you will have additional testing throughout the study period including
medical history, physical examination and imaging. This additional care is equivalent to
standard cancer care you would receive if you were not enrolled in the study.
Computerized tomography (CT) will be performed throughout the study duration to
monitor for response to the drug regimen and tumor size. CT imaging might be done
more frequently during the study than you would receive if you received standard care.
At the beginning of the treatment you will have imaging studies to evaluate tumor size
every 6 weeks for 24 weeks and every 12 weeks thereafter until either disease
progression or discontinuation. If you respond to treatment, there will be another
confirmatory scan ≥ 4 weeks later.
A small blood sample will be taken for routine blood testing for electrolytes, blood
counts and to measure liver and kidney function and monitor for infection throughout
the study duration. This routine blood testing will be repeated before each ipilimumab
dose.
If you are a female participant, you will be asked for a urine sample for
pregnancy testing at every visit. Both female and male participants will be asked to use
adequate birth control method throughout the duration of the study and 3 months after
the administration of the last dose of nivolumab/ipilimumab. You will be asked to report
all side effects to your provider as soon as they occur during study duration and up to 3
months after the administration of the last nivolumab/ ipilimumab dose.
This study is planned to run for a total of 18 months. During this trial, you must
agree not to take other anti-cancer medication (chemotherapy or immunotherapy) or
supplements that has not been prescribed by your study provider. You also cannot be
taking immunosuppressant medications, the most common of which is corticosteroids.
Inhaled and topical forms of corticosteroids are allowed during the trial period.
Participants will be randomly assigned to Arm A (nivolumab/ipilimumab plus
aspirin) or Arm B (nivolumab/ipilimumab plus celecoxib) by study administrators. As a
participant, you must agree to adhere to the assignment and take the home
medications as prescribed. Dose adjustment of these medications will not be allowed. If
dose adjustment is necessary for any reason, you will no longer be able to participate in
the study. The treatment will begin within 5 business days of randomization.
If you are in Arm A, you will receive weight-based infusions of nivolumab and
ipilimumab and a fixed dose of aspirin. If you are in Arm B, you will receive weightbased infusions of nivolumab and ipilimumab and a fixed dose of celecoxib. You will
receive nivolumab and ipilimumab every 3 weeks in the beginning for a total of four
doses followed by nivolumab only infusions every other week. The total number of
infusions will be decided based on whether you respond to treatment and how well you
respond to treatment. You might receive the nivolumab infusions until the 18-month
mark. Each visit to Yale New Haven Hospital will last between 1 and 3 hours and a half
hours. The doses and allocation to each group are not determined by your clinician and
cannot be changed once assigned. An equal number of participants will be assigned to
either arm. Once assigned, you will be required to adhere to the medication regimen in
the assigned arm. You will be asked to keep a log of the home medication portion of the
study (aspirin or celecoxib) and bring the log to every appointment. You will also fill out
two questionnaires in the beginning and every 6 weeks that will ask you about your
overall wellbeing. These questionnaires generally take about 11 minutes to complete.
What are the risks and discomforts of participating?
The risks of taking this new drug combination is not yet known, thus there may or may
not be risks associated with this treatment. You may experience side effects of the drugs
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used in this study You will be closely monitored during the trial period and you will be
asked to report any side effects to your provider as soon as they occur. Individually, all
components of the treatment regimen have been studied and found to have side effects
that range from mild and manageable to very serious, including a small risk of death. All
efforts will be made to make you comfortable during the treatment period and treat side
effects. If the side effects become serious or life threatening, you will receive immune
suppressant medication that reverses the effect of the study drugs. If you are not able to
tolerate the drugs, your participation in the study will be stopped. You should seek
emergency evaluation by calling 911 or going to the Emergency Department in case you
experience severe side effects to the medications. Most side effects go away once study
medications are stopped, but there is a chance that side effects become permanent.
Nivolumab and ipilimumab are FDA-approved biological agents for a group of colorectal
cancer patients who have the marker called microsatellite instability high (MSI-H) or
deficient mismatch repair (dMMR) to help the body’s immune respond better in
eliminating the cancer. This group that does not include the type of cancer that you have
(Microsatellite stable, MSS), thus the safety information comes mostly from studying the
other group. Ipilimumab has the highest potential to cause discomforts and risks among
the study drugs used, but in this study, it is used in what is considered a low dose.
Patients in previous studies that used this drug combination most commonly
experienced diarrhea, tiredness and itchiness. About one third of the patients had more
serious side effects such as elevated liver enzymes, elevated lipase (a pancreatic
enzyme), low blood counts, and bowel inflammation. About 13 out of 100 patients had to
discontinue treatment because of serious side effects such as kidney injury or
autoimmune liver inflammation. Thus, while taking the study medications, there is a
chance that you will experience some of these side effects. There is a chance that you
will have to discontinue this study because of the side effects and hospitalization to treat
the side effects might be necessary.
Celecoxib and aspirin are non-steroidal anti-inflammatory drugs (NSAIDs) that are
commonly used to treat inflammatory diseases such as arthritis at the dose that is used
in the study (Aspirin 325mg daily or Celecoxib 400mg daily). Aspirin at a lower dose
(100mg daily) is also used for colon cancer prevention. Aspirin at the 81mg daily dose is
also used as an anti-platelet agent to prevent blood clots in the prevention of stroke or
heart attack.
The most common side effects of aspirin are heartburn, nausea, vomiting and stomach
pain. Elevated liver enzymes were also reported as well as very rare cases of kidney
impairment and failure. There is also an increased risk of bleeding. The most serious
side effects are rare but include bleeding from a stomach ulcer, kidney failure or aspirinexacerbated respiratory disease. We take precautions that patients at risk for these
serious side effects are not participating in this study. The most common side effects of
celecoxib are dyspepsia, nausea, diarrhea and stomach pain. Side effects will be
managed by your clinician; however, you might need to discontinue treatment if you
have a serious bleeding from an ulcer or if your kidney function significantly worsens.
To receive nivolumab and ipilimumab infusions, you will have to have an IV-line placed.
IV-line placements are common procedures but they can be uncomfortable. Mild pain
around the IV site is common but goes away quickly when the IV is removed.
To monitor the progress of your tumors, you will need to have CT or MRI scans
periodically. CT scans will expose you to a high dose of radiation. Repeated doses of
radiation can be harmful on the long run. MRI studies do not expose you to harmful
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radiation but take longer and can be uncomfortable as you must stay still laying on your
back for long periods of time. If you suffer from claustrophobia, you might not be able to
tolerate MRI scans.
How will I know about new risks or important information about the study?
We will tell you if we learn any new information that could change your mind about taking
part in this study.
How can the study possibly benefit me?
You may or may not benefit from participating in this trial that will study the benefits and
potential harms of this new combination therapy. While patients have been taking this
medication combination previously, the potential benefits and safety of this combination
have not been previously investigated. Researchers and medical providers think that this
new combination will be more effective in treating cancer than receiving the two immune
checkpoint therapy drugs (nivolumab and ipilimumab) alone but it is not known in
advance who will personally benefit or experience adverse events while taking this
medication combination.
How can the study possibly benefit other people?
The benefits to science and other people may include a better understanding of how we
can make the type of colon cancer patients that you belong to (microsatellite stable,
MSS) respond to treatment as well as the group these medications are currently FDA
approved for (MSI-H) and which patients in your group will be good candidates for this
treatment in the future. We are hoping that the results of this study will lead to new
treatments for patients with your type of cancer.
Are there any costs to participation?
If you take part in this study, you will not have to pay for any services, supplies, study
procedures, or care that are provided for this research only (they are NOT part of your
routine medical care). The study medications ipilimumab, nivolumab, aspirin or celecoxib
will be provided to you at no cost. However, there may be additional costs to you. These
can include costs of transportation and your time to come to the study visits. You or your
health insurance must pay for services, supplies, procedures, and care that are part of
your routine medical care. You will be responsible for any co-payments required by your
insurance.
Will I be paid for participation?
You will not be compensated for participating in this study. There is no reimbursement
for traveling expenses to the study site.
What are my choices if I decide not to take part in this study?
Instead of participating in this study, you have some other choices.
You could:
• The same treatment combination is not available outside of this study for the type
of colorectal cancer you have (microsatellite stable (MSS) or proficient mismatch
repair pMMR). You might receive the standard of care treatment decided by you
and your oncologist. The main treatment options for colorectal cancer that spread
to distant sites are traditional chemotherapy, anti-VEGF or EGFR therapy. The
first line chemotherapeutic agents are FOLFOX (folinic acid (leucovorin),
fluorouracil (5FU) and oxaliplatin), FOLFIRI (folinic acid, 5FU and irinotecan),
Capecitabine and 5FU/leucovorin have been used with or without the anti-
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•
•

angiogenic agent bevacizumab. For high tumor burden or rapidly progressing
disease the quadruple chemotherapy FOLFOXIRI (folinic acid, fluorouracil,
oxaliplatin, irinotecan) can be considered. For refractory colon cancer drugs
regorafenib or trifluridine/tipiracil are recommended. Some patients in this study
have already tried these therapies and they didn’t work for them. If you have not
tried these therapies, you might benefit from trying them. The benefit of
chemotherapeutic agents is that they are well studied and have known side
effects. The risk associated with chemotherapy is the uncomfortable and
sometimes toxic side effects. The side effects of chemotherapy vary based on
the combination but the most commonly reported are diarrhea, neuropathy
(numbness and tingling sensation in the arms and legs), fatigue, hair loss and
cold sensitivity. Some side effects, such as neuropathy can be treatment limiting
and irreversible. You should further discuss your chemotherapy options with your
oncologist.
Take part in another study. You might also seek to participate in another study
listed at www.clinicaltrials.gov
Receive comfort care only, without any treatment for your disease. This option is
called palliative care. You and your oncologist may decide what options are best
for you.

How will you keep my data safe and private?
We will keep information we collect about you confidential. We will share it with others if
you agree to it or when we have to do it because U.S. or State law requires it. For
example, we will tell somebody if you we learn that you are hurting a child or an older
person.
Only research staff will have full access to the data we collect about you. Beyond
registration, the information pertaining to you will only include a registration number and
will not include any other information that can identify you, such as your name, birthday
or address. We will store research documents in a locked file cabinet. All research data
will be stored on a password protected computer.
When we publish the results of the research or talk about it in conferences, we will not
use your name. If we want to use your name, we would ask you for your permission. We
will also share information about you with other researchers for future research but we
will not use your name or other identifiers.
Identifiers might be removed from the identifiable private information or identifiable
biospecimens and that, after such removal, the information or biospecimens (eg. biopsy
or blood samples) could be used for future research studies or distributed to another
investigator for future research studies without additional informed consent from the
subject or the legally authorized representative, if this might be a possibility. We will not
ask you for any additional permission.
What Information Will You Collect About Me in this Study?
The information we are asking to use and share is called “Protected Health Information.”
It is protected by a federal law called the Privacy Rule of the Health Insurance Portability
and Accountability Act (HIPAA). In general, we cannot use or share your health
information for research without your permission. If you want, we can give you more
information about the Privacy Rule. Also, if you have any questions about the Privacy Rule
and your rights, you can speak to Yale Privacy Officer at 203-432-5919.
The specific information about you and your health that we will collect, use, and share
includes:
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• Research study records
• Medical and laboratory records of only those services provided in connection with
this Study.
• The entire research record and any medical records held by Yale New Haven
Hospital created from: 12/01/2019 to: 12/01/2021
• Records about phone calls made as part of this research
• Records about your study visits
• Information obtained during this research regarding
▪ HIV / AIDS test results
▪ Hepatitis infection
▪ Sexually transmitted diseases
▪ Other reportable infectious diseases
▪ Physical exams
▪ Laboratory, x-ray, biopsy and other test results
▪ Diaries and questionnaires
▪ The diagnosis and treatment of a mental health condition
▪ Use of illegal drugs or the study of illegal behavior
▪ Records about any study drug you received

How will you use and share my information?
We will use your information to conduct the study described in this consent form.
We may share your information with:
•
The U.S. Department of Health and Human Services (DHHS) agencies
•
Representatives from Yale University, the Yale Human Research Protection
Program and the Institutional Review Board (the committee that reviews, approves,
and monitors research on human participants), who are responsible for ensuring
research compliance. These individuals are required to keep all information
confidential.
•
The U.S. Food and Drug Administration (FDA) This is done so that the FDA can
review information about [the new drug product or device] involved in this research.
The information may also be used to meet the reporting requirements of drug
regulatory agencies.
•
The study sponsor or manufacturer of study drug/device
•
Drug regulatory agencies in other countries
•
Governmental agencies to whom certain diseases (reportable diseases) must be
reported
•
Health care providers who provide services to you in connection with this study.
•
Laboratories and other individuals and organizations that analyze your health
information in connection with this study, according to the study plan.
•
Co-Investigators and other investigators
•
Study Coordinator and Members of the Research Team
•
Data and Safety Monitoring Boards and others authorized to monitor the conduct of
the Study
We will do our best to make sure your information stays private. But, if we share
information with people who do not have to follow the Privacy Rule, your information will
no longer be protected by the Privacy Rule. Let us know if you have questions about this.
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However, to better protect your health information, agreements are in place with these
individuals and/or companies that require that they keep your information confidential.
Why must I sign this document?
By signing this form, you will allow researchers to use and disclose your information
described above for this research study. This is to ensure that the information related to
this research is available to all parties who may need it for research purposes. You always
have the right to review and copy your health information in your medical record.
What if I change my mind?
The authorization to use and disclose your health information collected during your
participation in this study will never expire. However, you may withdraw or take away your
permission at any time. You may withdraw your permission by telling the study staff or by
writing to Dr. Michael Hurwitz, 20 York Street, New Haven, CT, 06510 at the Yale
University, New Haven, CT 06520.
If you withdraw your permission, you will not be able to stay in this study but the care you
get from your doctor outside this study will not change. No new health information
identifying you will be gathered after the date you withdraw. Information that has already
been collected may still be used and given to others until the end of the research study to
insure the integrity of the study and/or study oversight.
Who will pay for treatment if I am injured or become ill due to participation in the
study?
If you are hurt or injured during this research, you will be given the medical care you may
need, but you or your insurance company will be billed for the cost of this treatment. No
financial compensation is available for injury or lost wages. You do not give up any of
your legal rights by signing this consent form.
What if I want to refuse or end participation before the study is over?
Taking part in this study is your choice. You can choose to take part, or you can choose
not to take part in this study. You also can change your mind at any time. Whatever
choice you make, you will not lose access to your medical care or give up any legal
rights or benefits.
We would still treat you with standard therapy or, at your request, refer you to a clinic or
doctor who can offer this treatment. Not participating or withdrawing later will not harm
your relationship with your own doctors or with this institution.
To withdraw from the study, you can call a member of the research team at any time and
tell them that you no longer want to take part.
The researchers may withdraw you from participating in the research if necessary, e.g.
because of development of serious side effects.
What will happen with my data if I stop participating?
When you withdraw your permission, no new health information identifying you will be
gathered after that date. Information that has already been gathered may still be used
and given to others until the end of the research study, as necessary to insure the
integrity of the study.

73

Who should I contact if I have questions?
Please feel free to ask about anything you don't understand.
If you have questions later or if you have a research-related problem, you can call the
Principal Investigator Dr.Michael Hurwitz at (203) 400-4822.
If you have questions about your rights as a research participant, or you have complaints
about this research, you call the Yale Institutional Review Boards at (203) 785-4688 or
email hrpp@yale.edu.
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as
required by U.S. Law. This Web site will not include information that can identify you. At
most, the Web site will include a summary of the results. You can search this Web site at
any time.
Authorization and Permission
Your signature below indicates that you have read this consent document and that you
agree to be in this study.
We will give you a copy of this form.

Participant Printed Name

Participant Signature

Date

Person Obtaining Consent Printed
Name

Person Obtaining Consent Signature

Date

Complete if the participant is not fluent in English and an interpreter was used to obtain
consent. Participants who do not read or understand English must not sign this full consent
form, but instead sign the short form translated into their native language. This form should
be signed by the investigator and interpreter only. If the interpreter is affiliated with the
study team, the signature of an impartial witness is also required.

74

Print name of interpreter: ______________________________________

Signature of interpreter: ___________________________________

Date: _________

An oral translation of this document was administered to the participant in
_____________ (state language) by an individual proficient in English and
____________ (state language).
Print name of impartial witness: __________________________________

Signature of impartial witness: ________________________________Date: _________
See the attached short form for documentation.
Consent Form Template (Biomedical)
Version 01/21/2019

APPENDIX H IPILIMUMAB AND NIVOLUMAB DOSE CALCULATIONS
A. Ipilimumab 1ml/kg dose, supplied as 5mg/ml (40ml or 10ml single use vials)
To calculate the total dose:
Patient’s weight in kg x 1mg dose = total dose in mg
To calculate the total infusion volume:
Total dose in mg / 5mg/ml (as supplied) = total infusion volume in ml
To calculate the infusion rate:
Total infusion volume in ml / 60minutes = rate of infusion in ml/min
B. Nivolumab 3ml/kg dose supplied as 10mg/ml (4ml, 10ml or 24ml single use vials)
To calculate the total dose:
Patient’s weight in kg x 3mg dose = total dose in mg
To calculate the total infusion volume:
Total dose in mg / 10mg/ml (as supplied) = total infusion volume in ml
To calculate the infusion rate:
Total infusion volume in ml / 90minutes = rate of infusion in ml/min
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Reference:
Yervoy package insert In: Company Bristol-Myers Squibb, ed.
Opdivo (nivolumab). In: Bristol-Myers Squibb, ed. [package insert]. www.opdivo.com.

APPENDIX I PATIENT REGISTRATION FORM

Yale Cancer Center
Smilow Cancer Hospital
Yale School of Medicine
Department of Medical Oncology
Principal Investigator: Michael Hurwitz, MD, PhD.
Patient’s Name: (Last, First, Middle initial) ______________, _________________, ___
Patient Registration Number:
DOB (MM/DD/YYYY):__/__/____
Social Security Number: ___-__-____
Demographics:
Sex assigned at birth: ☐Male ☐Female
Age: ☐18-24 ☐25-34 ☐35-44 ☐45-54 ☐55-64 ☐65-74 ☐75-84 ☐85-94
Race: ☐White ☐Hispanic or Latino ☐Black or African American ☐Native
American or American Indian ☐Pacific Islander or Asian ☐Other
Diagnosis of primary tumor: (MM/DD/YYYY)__/__/____
Diagnosis of metastasis: (MM/DD/YYYY)__/__/____
Sites of metastasis: _______________________________________________________
Histologic characterization of tumor: _________________________________________
Confirmed MSS or pMMR ☐ Histochemistry or ☐ PCR or ☐ MSIsensor
Date performed (MM/DD/YYYY) __/__/____
History of Lynch syndrome: ☐ Yes ☐ No
Immunoscore: ☐ 1 ☐ 2 ☐ 3 ☐ 4
Treatment dates: _________________ Treatment regimen/dose: ___________________
Treatment dates: _________________ Treatment regimen/dose: ___________________
Treatment dates: _________________ Treatment regimen/dose: ___________________
Medical History/dates:
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
Surgical History/dates:
________________________________________________________________________
________________________________________________________________________
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________________________________________________________________________
Medications:
Name: _________________________ Dose:____________________________________
Name: _________________________ Dose:____________________________________
Name: _________________________ Dose:____________________________________
Name: _________________________ Dose:____________________________________
Name: _________________________ Dose:____________________________________
Name: _________________________ Dose:____________________________________
Name: _________________________ Dose:____________________________________
Name: _________________________ Dose:____________________________________
Name: _________________________ Dose:____________________________________
Name: _________________________ Dose:____________________________________
Allergies:
Name: ________________________ Reaction:__________________________________
Name: ________________________ Reaction:__________________________________
Name: ________________________ Reaction:__________________________________
Name: ________________________ Reaction:__________________________________
Name: ________________________ Reaction:__________________________________
Name: ________________________ Reaction:__________________________________
ECOG performance status
☐ 0 Fully active, able to carry on all pre-disease performance without restriction
☐ 1 Restricted in physically strenuous activity but ambulatory and able to carry out work
of a light or sedentary nature, e.g., light house work, office work
Smoking history:
☐Never smoker ☐Former smoker ☐Current smoker Pack per year: ____________

APPENDIX J SAMPLE SIZE CALCULATION

n n 1 r1 r2
37 20
38 17
39 15
41 14

1
1
1
1

6
6
6
6

Type 1
Error
0.0373
0.0404
0.0427
0.0500

Power EN0
0.8018 29.0
0.8077 26.3
0.8025 24.1
0.8105 23.4

Probability of early
stopping
0.4706
0.5576
0.6202
0.6527

n is the total number of subjects
n1 is the number of subjects accrued during stage 1
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Interval for w Comment
[0.7304,1]
Minimax
[0.6853,0.7303]
[0.2693,0.6852]
[0,0.2692]
Optimal

r1, if r1 or fewer responses are observed during stage 1, the trial is stopped early for
futility
r2, if r2 or fewer responses are observed by the end of stage two, then no further
investigation of the drug is warranted
EN0 is the expected sample size for the trial when response rate is p0
Interval for w is the set of values w such that the design minimizes w * n + (1 – w) * EN0
The null hypothesis that the true objective response rate is 8.7%, as observed in the
CheckMate 142 trial will be tested against two one-sided alternatives. A 15% effect size
will be tested for clinical significance using a Type I (one sided) error rate of 0.5 and type
II error of 0.2, yielding an 80% power. p1, which is the response probability of the good
drug is 23.7%, calculated as p0 + 15% effect size. The 15% is an arbitrarily chosen effect
size that is widely used in cancer drug trials. The Simon’s two stage design calculator
uses this statistical input to calculate n which is the total number of subjects, n1, the
number of subjects accrued during stage 1, r1, the value for which if r1 or fewer responses
are observed during stage 1, the trial is stopped early for futility, r2, the value for which if
r2 or fewer responses are observed by the end of stage two, then no further investigation
of the drug is warranted, EN0 which is the expected sample size for the trial when
response rate is p0 (response probability of poor drug).
References:
1. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled
clinical trials. 1989;10(1):1-10.
2. Jung SH, Lee TY, Kim KM, George S (2004). Admissible two-stage designs for
phase II cancer clinical trials, Statistics in Medicine 23: 561-569.
3. Simon’s Two stage design calculator
http://cancer.unc.edu/biostatistics/program/ivanova/SimonsTwoStageDesign.aspx

APPENDIX K RESPONSE EVALUATION CRITERIA IN SOLID TUMORS
(RECIST) V.1.1
ORR: Investigator-assessed objective response rate calculated as patients with best
response or complete response (CR) or partial response (PR) divided by the number of
patients treated.
OS: Time from the first dose to death.
PFS: Progression free survival defined as time from first dose to first documented
progression or death resulting from any cause, whichever occurred first.
DCR: Patients with CR, PR or stable disease (SD) for ≥ 12 weeks divided by the number
of patients treated.
PRO: Patient-reported outcomes, such as functioning, symptoms and quality of life
(QOL).
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APPENDIX L PATIENT STUDY CHECKLIST
Patient’s Name (Last, First, Middle initial): _____________, ________________, _____
DOB (DD/MM/YYYY):__/__/____
Registration number: ____________
Proposed treatment start date: __/__/____
Actual treatment start date: __/__/____
☐ Passed Eligibility Checklist
☐ Signed Consent to Participate in Study
☐ Completed Patient Registration Form
☐ Randomized to Treatment Arm A or Treatment Arm B

APPENDIX M CRITERIA FOR TREATMENT DELAY AND RESUMPTION
Adopted from Supplemental Tables for: Safety of Nivolumab Plus Low-Dose Ipilimumab
in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient
Metastatic Colorectal Cancer Michael Morse et al. Table S1. For grading of adverse
events please see Appendix D (CTCAE) Version 5.0
Treatment Delay Criteria:
•Any grade ≥2 non–skin-specific TRAE, with the following exceptions:
- Grade 2 treatment-related fatigue or laboratory abnormalities do not require a
treatment delay
•Any grade 3 skin TRAE
•Any grade 3 treatment-related laboratory abnormality, with the following exceptions for
asymptomatic amylase or lipase, AST, ALT, or total bilirubin:
- Grade 3 amylase or lipase abnormalities that are not associated with symptoms or
clinical manifestations of pancreatitis do not require a dose delay (consultation
recommended for grade 3 amylase or lipase abnormalities)
- In patients with baseline AST, ALT, or total bilirubin within normal limits, treatment
would be delayed in case of treatment-related grade ≥2 toxicity
- In patients with baseline AST, ALT, or total bilirubin within the grade 1 toxicity
range, treatment would be delayed in case of treatment-related grade ≥3 toxicity
Treatment resumption criteria:
Patients can resume treatment when the TRAE resolved to grade ≤1 or to baseline values,
with the following exceptions:
•Patients may resume treatment in the presence of grade 2 fatigue
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•Patients who have not experienced a grade 3 skin TRAE may resume treatment in the
presence of grade 2 skin toxicity
•Patients with baseline grade 1 AST/ALT or total bilirubin who require dose delays for
reasons other than a 2-grade shift in AST/ALT or total bilirubin may resume treatment in
the presence of grade 2 AST/ALT or total bilirubin
•Treatment-related pulmonary toxicity, diarrhea, or colitis must have resolved to baseline
before treatment is resumed
•Treatment-related endocrinopathies adequately controlled with only physiologic
hormone replacement may resume treatment
Abbreviations: TRAE – treatment-related adverse events, ALT- alanine aminotransferase,
AST- aspartate aminotransferase
Reference:
Morse MA, Overman MJ, Hartman L, et al. Safety of Nivolumab plus Low-Dose
Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch RepairDeficient Metastatic Colorectal Cancer. The oncologist. 2019.
APPENDIX N DEFINITIONS OF ADVERSE EVENTS WITH IMMUNE
CHECKPOINT INHIBITOR THERAPY
Treatment Related Adverse Events (TRAEs) are defined as adverse events (AEs)
of special clinical interest meeting defined criteria that were grouped by specific
categories such as endocrine, GI, hepatic, pulmonary, renal and skin events and had a
potential immunologic etiology.
Immune mediated adverse events (IMAEs) are defined as specific events that
includes diarrhea and colitis, hepatitis, pneumonitis, nephritis and renal dysfunction, rash,
and endocrine events such as adrenal insufficiency, hypophysitis,
hypothyroidism/thyroiditis, hyperthyroidism and diabetes mellitus.
Reference:
Morse MA, Overman MJ, Hartman L, et al. Safety of Nivolumab plus Low-Dose
Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch RepairDeficient Metastatic Colorectal Cancer. The oncologist. 2019.
APPENDIX O ADEQUATE ORGAN FUNCTION LABORATORY VALUES
Hematological
Absolute leukocyte count
Absolute lymphocyte count
(ALC)
Absolute neutrophil count
(ANC)
Platelets

≥2500 /mcL
≥500 /mcL
≥1500 /mcL
≥100,000 / mcL
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Hemoglobin
Hepatic
Serum total bilirubin
or
Direct bilirubin
AST and ALT
Albumin

≥9 g/dL or ≥ 5.6 mmol/L without transfusion or EPO
dependency (within 7 days of assessment)
≤ 1.5 X ULN
or
≤ ULN for subjects with total bilirubin levels > 1.5
ULN
≤ 2.5 X ULN OR
≤ 5 X ULN for subjects with liver metastases
> 2.5 mg/dL

Coagulation
International Normalized Ratio ≤1.5 X ULN unless subject is receiving anticoagulant
(INR) or Prothrombin Time
therapy as long as PT or PTT is within therapeutic range
(PT)
of intended use of anticoagulants
≤1.5 X ULN unless subject is receiving anticoagulant
Activated Partial
therapy as long as PT or PTT is within therapeutic range
Thromboplastin Time (aPTT)
of intended use of anticoagulants
Renal
Serum creatinine
≤1.5 X upper limit of normal (ULN)
or
or
Measured or calculated
creatinine clearance
≥60 mL/min for subject with creatinine levels > 1.5 X
(GFR can also be used in place institutional ULN
of creatinine or CrCl)
Reference:
Eisenhauer EA, Twelves C, Buyse M, Phase I Cancer Trials, a Practical Guide, Oxford
University Press, 2015
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APPENDIX P SUMMARY OF CURRENT PHASE I/II TRIALS
Title

Study type

Nivolumab, Ipilimumab
and COX2-inhibition in
Early Stage Colon
Cancer: an Unbiased
Approach for Signals of
Sensitivity (NICHE)
[NCT03026140]

Phase II,
Interventional,
open label, single
center,
randomized
allocation,
parallel
assignment.

RACIN, A Phase I
Study of the
Combination of
Nivolumab Plus
Ipilimumab
Associated With Lowdose Radiation,
Aspirin, and Low-dose
Cyclophosphamide,
Followed by
Nivolumab
Maintenance, in
Patients With
Advanced, TILnegative Solid Tumors
[NCT03728179]

Phase Ia/Ib
Interventional,
non-randomized,
sequential
assignment, dose
escalation of
radiation, open
label

Enrollment

Indication

Intervention

60

Early stage (stage
1-3) CRC (both
MSS and MSI-H)

Neoadjuvant
Control arm: single dose
of ipilimumab 1mg/kg
on day 1 and two cycles
of nivolumab 3mg/kg
on day 1 and 15,
respectively.
Experimental group:
single dose of
ipilimumab 1mg/kg on
day 1, two cycles of
nivolumab 3mg/kg one
day 1 and 15 and 200mg
celecoxib daily until the
day before surgery

50

Patients with
advanced, TILnegative Solid
Tumors

Cyclophosphamide:
200mg/m2 (IV) Q2W
from cycle C0 to C4.
Nivolumab: 240 mg IV
Q2W from cycle C1 to
C4.
Ipilimumab: 1mg/kg
will be administered as
IV every 6 weeks
(Q6W) from cycle C1 to
C4 Aspirin: 300mg
orally daily from cycle
C1 to C4. Dose
escalation of radiation:
0.5Gy, 1Gy, 2Gy, 3Gy

82

Primary outcome
measures
Incidence of
adverse events
during the
treatment and
follow-up (safety)
Per CTCAE v 4.0

Secondary outcome
measures
1. Immune activating
capacity of short-term preoperative immunotherapy
[Time Frame: within 2 years
after study completion]
identify underlying potential
escape mechanisms by
comparing pre-treatment
and post-treatment biopsies
2. Relapse free survival
[Time Frame: 3-5 years after
last patient inclusion]

Phases Ia and Ib:
Incidence of
TreatmentEmergent Adverse
Events
(Safety and
Tolerability)
[Time Frame: 3.5
years] Phase Ia
and IB: Toxicity
and tolerability
per CTCAEv.4.03
2. Maximum
Tolerated dose
(MTD)

1. Objective response rate
(ORR)[Time Frame: 3.5
years] Per (RECIST) v.1.1.
2. Disease Control Rate
(DCR) [Time Frame: 6,12
and 24 months] Per RECIST
v.1.1
3. Progression free survival
(PFS) rate
[Time Frame: 6,12 and 24
months] Per RECIST v.1.1.
4. Time to Progression
(TTP): [Time Frame: 3.5
years] Per RECIST v.1.1

[Time Frame: 3.5
years]
PD-1 Antibody
Combined With COX
Inhibitor in MSIH/dMMR or High TMB
Colorectal Cancer
[NCT03638297]

Phase II,
Interventional,
single group,
open label

54

MSI-H/dMMR or
High TMB
Colorectal Cancer

PD-1 antibody + cox
inhibitor BAT1306 +
aspirin
BAT1306 100mg on
day 1 + aspirin 200mg
oral (celebrex 400mg
oral when there is
contraindication to
aspirin) on day 1-21
every three weeks

CR (complete
response) + PR
(partial response)
rate according to
the RECIST
version 1.1
guidelines.

An Open Label Phase II
Study Combining
Nivolumab and
Celecoxib in Patients
With Advanced " Cold "
Solid Tumors (NICECOMBO)
[NCT03864575]

Phase II,
Interventional,
Single group
assignment,
Simon’s twostage Minimax
design, open
label

68

Cancer types with
an indication of
treatment with antiPD1 antibodies,
metastatic, IDO1
positive (≥5%
expression of tumor
cells) and non Tcell infiltrated
tumors (<1% T
cells infiltrating the
tumor bed)

Celecoxib 400 mg/d
nivolumab 240 mg
every two weeks

ORR Objective
response rate
[Time Frame: at
week 12 from
onset of
treatment]

83

5. Overall survival (OS)
[Time Frame: 12 and 24
months]
1. Progression free survival
[Time Frame: 2 years]
2. Overall survival time
[Time Frame: 5 years]
3. Disease control rate
[Time Frame: 6 months]
Per RECIST version 1.1
4. Toxicity assessed using
the NCI common toxicity
criteria, version 4.0.
[Time Frame: 2 years]
5. Duration of response
[Time Frame: 2 years]
Number of
participants with treatmentrelated adverse events as
assessed by CTCAE v4.0
[Time Frame: from first
dose to day 28 post last
dose]
2. Efficacy - Duration of
response (DOR)
[Time Frame: From date of
randomization until the date
of first documented
progression or date of death
from any cause, whichever
came first, assessed up to 60
months]
per RECIST v1.1
3. Efficacy - Time to
response (TTR)
[Time Frame: From onset of

PRIMMO: a phase II
study combining PD-1
blockade, radiation and
immunomodulation to
tackle cervical and
uterine cancer
[NCT03192059]

Phase II, multicenter, openlabel, nonrandomized, 3cohort study with
a safety run-in in

43+

Recurrent/refractory
cervical carcinoma,
endometrial
carcinoma or
uterine sarcoma

84

Pembrolizumab 200mg
q3w IV, Radiation 3
fractions of 8Gy 48
hours apart, Vitamin D
2000IU daily,
Lansoprazole 180mg
uneven weeks, 30mg
even weeks, aspirin
325mg daily, cyclophosphamide 50mg
daily, curcumin 2g daily

Objective
response rate
(ORR) at week 26
per immunerelated response
criteria (irRC)

treatment to response of
cancer through study
completion, an average of
12 months is expected] Per
RECIST v1.1.
4. Disease control rate
(DCR) [Time Frame: at
week 12 from onset of
treatment]
Per RECIST v1.1.
5. Progression-free survival
(PFS) [Time Frame: From
date of randomization until
the date of first documented
progression or date of death,
whichever comes first,
assessed up to 60 months ]
Per RECIST v1.1), or death
due to any cause, if
occurring sooner than
progression.
6. Overall survival (OS)
[Time Frame: From date of
randomization until the date
of death, assessed up to 60
months]
Safety per (CTCAE4.0), the
ORR at week 26 per
RECIST criteria, the best
overall response (BOR),
progression-free survival
(PFS), overall survival (OS)
and quality of life (QoL)

APPENDIX Q DEFINITION OF ADVERSE EVENTS AND SERIOUS ADVERSE
EVENTS
Adverse events (AE) are defined as any untoward or unfavorable occurrence in a
human research subject (physical or psychological harm) temporally associated with the
individual’s participation in the research (whether or not considered related to
participation in the research).
Serious adverse events (SAE) are defined as any adverse event that results in any
of the following outcomes: death, a life-threatening experience, inpatient hospitalization
or prolongation of existing hospitalization, a persistent or significant
disability/incapacity, a congenital anomaly/birth defect, or any other adverse event that,
based upon appropriate medical judgment, may jeopardize the subject’s health and may
require medical or surgical intervention to prevent one of the other outcomes listed in this
definition.
Reference:
Administration OoR. IRB Policy 710 Reporting Unanticipated Problems Involving Risks
to Subjects or Others, including Adverse Events. In: University Y, edApril 15
2014
APPENDIX R BRIEF OUTLINE OF AMERICAN SOCIETY OF CLINICAL
ONCOLOGY (ASCO) GUIDELINES BY CTCAE GRADE
There will be a high level of suspicion that any new adverse symptom might be
immunotherapy related. In general, Grade 1 toxicities will be closely followed without
treatment interruption. Exceptions are some neurologic, cardiac and hematologic
toxicities. Treatment will be held for most Grade 2 toxicities and will be resumed when
symptoms and/or laboratory abnormalities revert to Grade 1 or less. A 0.5-1.0mg/kg/day
prednisone equivalent corticosteroid dose may be administered.
Treatment will be held for Grade 3 toxicities and high dose corticosteroids will be
initiated (prednisone equivalent of 1-2mg/kg/day, (alternatively methylprednisolone IV
1-2mg/kg/day). Infliximab may be given if symptoms and/or laboratory values don’t
improve within 48-72 hours with high dose corticosteroids. In case of liver toxicity, we
will use non-TNF-α agents instead to avoid the hepatotoxic properties of Infliximab.
Treatment might be reinitiated when symptoms and/or laboratory values return to Grade
1 or less. There will be no dose adjustments made. Treatment will be permanently
discontinued in case of Grade 4 toxicity, except for endocrinopathies that can be
generally managed by hormone replacement.
Reference:
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse
Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American
Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical
Oncology. 2018;36(17):1714-1768.
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